# Safety Assessment of Polysorbates as Used in Cosmetics

Status: Release Date: Panel Meeting Date: Tentative Amended Report for Public Comment March 31, 2015 June 15-16, 2015

All interested persons are provided 60 days from the above date to comment on this safety assessment and to identify additional published data that should be included or provide unpublished data which can be made public and included. Information may be submitted without identifying the source or the trade name of the cosmetic product containing the ingredient. All unpublished data submitted to CIR will be discussed in open meetings, will be available at the CIR office for review by any interested party and may be cited in a peer-reviewed scientific journal. Please submit data, comments, or requests to the CIR Director, Dr. Lillian J. Gill.

The 2015 Cosmetic Ingredient Review Expert Panel members are: Chair, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; Ronald A. Hill, Ph.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; James G. Marks, Jr., M.D.; Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The CIR Director is Lillian J. Gill, D.P.A. This report was prepared by Lillian C. Becker, Scientific Analyst/Writer.

© Cosmetic Ingredient Review

1620 L Street, NW, Suite 1200 & Washington, DC 20036-4702 & ph 202.331.0651 & fax 202.331.0088 & cirinfo@cir-safety.org

## ABSTRACT

This is a safety assessment of polysorbates as used in cosmetics. These ingredients mostly function as surfactants in cosmetics. The safety assessment combined the polysorbates reviewed in 3 former safety assessments with polysorbates that had not been assessed for safety into 1 report. The Panel reviewed relevant data related to these ingredients. The Cosmetic Ingredient Review (CIR) Expert Panel (Panel) concluded that polysorbates were safe as cosmetic ingredients in the practices of use and concentration of this safety assessment when formulated to be nonirritating. This conclusion supersedes the conclusion reached in the 3 former safety assessments.

## **INTRODUCTION**

This is a re-review of the available scientific literature and unpublished data relevant to assessing the safety of polysorbates as used in cosmetics (Table 1). This safety assessment combines polysorbates reviewed previously in 3 safety assessments with other polysorbates that have not been reviewed by the CIR Panel into a group of 82 polyethoxylated sorbitan or sorbitol esters of fatty acids (Table 2). These ingredients have a common core structure of sorbitan or sorbitol, etherified with polyethyoxy (PEG) chains, and esterified with fatty acids. These ingredients mostly function as surfactants in cosmetics.

In the original safety assessment published in 1984, the CIR Panel concluded that 9 polysorbates were safe as used These ingredients are:<sup>1</sup>

Polysorbate 20Polysorbate 65Polysorbate 21Polysorbate 80Polysorbate 40Polysorbate 81Polysorbate 60Polysorbate 85Polysorbate 61Polysorbate 85

Other polysorbates, which are also polyethoxylated sorbitan or sorbitol esters of fatty acids and contain a PEG moiety, have been reviewed by the CIR Panel. In 2000<sup>2</sup>, a safety assessment was published with a safe-as-used conclusion for the following 33 PEG sorbitan/sorbitol fatty acid esters:

PEG-20 sorbitan cocoate	PEG-40 sorbitan stearate
PEG-40 sorbitan diisostearate	PEG-60 sorbitan stearate
PEG-2 sorbitan isostearate	PEG-20 sorbitan tetraoleate
PEG-5 sorbitan isostearate	PEG-30 sorbitan tetraoleate
PEG-20 sorbitan isostearate	PEG-40 sorbitan tetraoleate
PEG-40 sorbitan lanolate	PEG-60 sorbitan tetraoleate
PEG-75 sorbitan lanolate	PEG-60 sorbitan tetrastearate
PEG-10 sorbitan laurate	PEG-20 sorbitan triisostearate
PEG-40 sorbitan laurate	PEG-160 sorbitan triisostearate
PEG-44 sorbitan laurate	PEG-18 sorbitan trioleate
PEG-75 sorbitan laurate	Sorbeth-40 hexaoleate (previously PEG-40 sorbitol
PEG-80 sorbitan laurate	hexaoleate)
PEG-3 sorbitan oleate	Sorbeth-50 hexaoleate (previously PEG-50 sorbitol
PEG-6 sorbitan oleate	hexaoleate)
PEG-80 sorbitan palmitate	Sorbeth-30 tetraoleate laurate (previously PEG-30
PEG-40 sorbitan perisostearate	sorbitol tetraoleate laurate)
PEG-40 sorbitan peroleate	Sorbeth-60 tetrastearate (previously PEG-60 sorbitol
PEG-3 sorbitan stearate	tetrastearate)
PEG-6 sorbitan stearate	

There were 2 ingredients that were included in the 2000 report, but were not listed in the *International Cosmetic Ingredient Dictionary and Handbook*<sup>3</sup> (*Dictionary*) at the time of the original review, and are not listed as cosmetic ingredients in the current *Dictionary*.<sup>4</sup> One is PEG-18 sorbitan trioleate, which has 1 use listed in the Food and Drug Administration's (FDA) Voluntary Cosmetic Registration Program (VCRP)<sup>5</sup> and is therefore included in this safety assessment. However, PEG-20 sorbitan tetraoleate has no uses listed in the VCRP, so is not included in this safety assessment.

In 2001<sup>6</sup>, a safety assessment was published with a safe-as-used conclusion for the following sorbitan beeswaxes:

Sorbeth-6 beeswax (formerly PEG-6 sorbitan beeswax) Sorbeth-8 beeswax (formerly PEG-8 sorbitan beeswax) Sorbeth-20 beeswax (formerly PEG-20 sorbitan beeswax) At the time of this safety assessment, the Panel had recommended that cosmetic formulations containing PEGs (specifically PEG-6, PEG-20, and PEG-75) not be used on damaged skin. Since then, PEGs have been re-reviewed and the Panel has removed the caveat that PEGs should not be used on damaged skin.<sup>7</sup>

A brief summary of pertinent data from each report is provided below. The original polysorbate reports can be found on the CIR website, <u>http://www.cir-safety.org/ingredients</u>. Please refer to the original reports for detailed information.

The following 35 ingredients, which are also polyethoxylated sorbitan or sorbitol esters of fatty acids, are proposed as additions to this group:

PEG-20 sorbitan oleate	Sorbeth-20 pentaisostearate
PEG-40 sorbitan oleate	Sorbeth-30 pentaisostearate
PEG-4 sorbitan stearate	Sorbeth-40 pentaisostearate
PEG-4 sorbitan triisostearate	Sorbeth-50 pentaisostearate
PEG-2 sorbitan trioleate	Sorbeth-40 pentaoleate
PEG-3 sorbitan tristearate	Sorbeth-20 tetraisostearate
Sorbeth-2 beeswax	Sorbeth-30 tetraisostearate
Sorbeth-2 cocoate	Sorbeth-40 tetraisostearate
Sorbeth-2 hexacaprylate/caprate	Sorbeth-50 tetraisostearate
Sorbeth-12 hexacocoate	Sorbeth-4 tetraoleate
Sorbeth-2 hexaisostearate	Sorbeth-6 tetraoleate
Sorbeth-2 hexalaurate	Sorbeth-30 tetraoleate
Sorbeth-2 hexaoleate	Sorbeth-40 tetraoleate
Sorbeth-6 hexastearate	Sorbeth-60 tetraoleate
Sorbeth-150 hexastearate	Sorbeth-3 tristearate
Sorbeth-3 isostearate	Sorbeth-160 tristearate
Sorbeth-6 laurate	Sorbeth-450 tristearate
Sorbeth-2/oleate/dimer dilinoleate crosspolymer	

The VCRP reported single uses for 3 other ingredients that are not listed in the Dictionary.<sup>8</sup> Since there are reported uses for these 3 ingredients, they are also included in this safety assessment:

PEG-30 sorbitan beeswax PEG-20 sorbitan laurate PEG-20 sorbitan stearate

CIR has conducted safety assessments of the acids and related chemical structure moieties of these ingredients (Table 2). The Panel concluded that beeswax, coconut acid, isostearic acid, lanolin acid, oleic acid, lauric acid, myristic acid, stearic acid, and multiple stearates were safe-as-used.<sup>9-17</sup> An array of alkyl esters and numerous PEGs were also assessed to be safe as used.<sup>7,18,19</sup> Sorbitan esters have been reviewed with safe-as-used conclusions.<sup>20-22</sup>

Much of the new data included in this safety assessment were found on the European Chemicals Agency (ECHA) website.<sup>23-25</sup> The ECHA website provides robust summaries of information generated by industry, and it is those summary data that are reported in this safety assessment when ECHA is cited. Some of this data are for generic sorbitan monolaurate, ethoxylated and sorbitan monostearate, ethoxylate; these chemicals fit the general definition of several of these ingredients with the same CAS No. (ie, polysorbate 21, PEG-10 sorbitan laurate, PEG-40 sorbitan laurate, polysorbate 20, PEG-44 sorbitan laurate, PEG-75 sorbitan laurate, and PEG-80 sorbitan laurate all have the CAS No. 9005-64-5). It is expected that data under these chemicals names are for one or some mixture of the ingredients with that CAS No and are useful for read across information.

## SUMMARIES OF PREVIOUS SAFETY ASSESSMENTS

#### Polysorbates, 1984

The Polysorbates are a series of polyoxyethylenated sorbitan esters that differ with respect to the number of polymerized oxyethylene subunits and the number and type of fatty acid moieties present.<sup>1</sup> They are used as general purpose, hydrophilic, nonionic surfactants in a variety of cosmetic products. Some of the Polysorbates are also approved by the Food and Drug Administration for use in various pharmaceuticals and food products.

Studies employing radioactive tracer techniques show that the Polysorbates are hydrolyzed by pancreatic and blood lipases; the fatty acid moiety is released to be absorbed and metabolized, whereas the polyoxyethylene sorbitan moiety is very poorly absorbed and is excreted unchanged. As expected, the Polysorbates are active at levels of biological structure and function from basic biochemical pathways to the cardiovascular and immune systems. Most or all of these effects can most likely be related to the surface active properties of the intact Polysorbate molecule.

Polysorbate 80 was shown to be nonmutagenic in the Ames and micronucleus tests. The polysorbates have been shown in numerous studies to be noncarcinogenic when administered in a variety of ways to laboratory animals, although

Polysorbate 80 produced some neoplastic changes in mixed mouse epidermal and dermal in vitro tissue culture. Multiple studies have shown that the Polysorbates enhance the activity of known chemical carcinogens while not actually being carcinogenic themselves. Proposed mechanisms of this tumor enhancement effect include induction of cellular hyperproliferation, inhibition of DNA repair, and others. The Polysorbates also exhibit tumor growth inhibition activity under certain conditions.

Extensive testing for acute and long-term oral toxicity in animals has resulted in evidence indicating the low order of toxicity with oral ingestion of the Polysorbates. Most of the reported toxicity can be attributed either directly or indirectly to the osmotic diarrhea caused by the polyoxyethylene sorbitan moiety retained within the intestinal lumen. Polysorbate 20 and product formulations containing 1.0 to 8.4 percent of Polysorbate 20, 40, 80, or 85 produced no evidence of acute or subchronic percutaneous toxicity, the only effects being erythema, edema, and desquamation at the site of application. Acute intravenous and intraperitoneal injection of the Polysorbates into rats or mice resulted in  $LD_{50}$  values indicative of a low order of parenteral toxicity. Daily intravenous injections of Polysorbates 60 and 80 into rabbits for up to 65 days produced pathology limited mainly to the renal and reticuloendothelial systems.

The Polysorbates showed little potential for rabbit and mouse skin irritation in acute studies. Those of the Polysorbates that were tested in subchronic skin irritation tests for up to 60 days produced local skin reactions ranging from minimal inflammation to necrosis. These changes were attributable to damage of epidermal cell membranes by the emulsifying action of the Polysorbates. The Polysorbates produced no more than minimal, transient eye irritation in Draize rabbit eye irritation tests. Polysorbate 80 produced superficial, mild damage to the intestinal mucosae of rabbits and rats. Polysorbate 20 produced no inflammation when applied to the hamster cheek pouch, and Polysorbate 40 caused no inflammation test showed moderate to strong skin sensitization to Polysorbate 20 in one study. Another guinea pig skin sensitization assay reported no evidence of skin sensitization to Polysorbates 65 and 80.

The Polysorbates have been ingested by human beings in situations ranging from an accidental administration of 19.2 g of Polysorbate 80 to an infant on 2 consecutive days to daily therapeutic administration of up to 6.0 g of Polysorbate 80 to adults for up to 4 years. These studies consistently showed little or no adverse effects from oral ingestion of the Polysorbates. Extensive clinical skin testing in the Schwartz prophetic patch test showed little potential for human skin irritation and no evidence of skin sensitization in a total of 580 subjects. A total of 1206 patients with eczema were tested in a chamber method 24-hour occlusive patch test for allergic contact dermatitis to a mixture of 5 percent Polysorbate 60 and 5 percent Polysorbate 80 in petrolatum; allergic reactions were shown by only 2 of the patients (< 0.2 percent). Several product formulations containing the Polysorbates have been tested for human skin sensitization on a total of 3481 subjects using a variety of testing methods; there were no reactions indicative of sensitization to any of the Polysorbates in these assays. Investigations with patients known to have skin disease revealed isolated instances of skin sensitization to Polysorbate 80 produced hemodynamic changes in 5 patients. Studies involving exposure to ultraviolet light showed no instance of photocontact sensitization to the Polysorbates, although there were isolated instances of mild irritation following UV exposure when testing product formulations containing the Polysorbate Polysorbate 80 produced hemodynamic changes in 5 patients.

#### PEGs Sorbitan/Sorbitol Fatty Acid Esters 2000

The PEGs Sorbitan/Sorbitol Fatty Acid Esters are ethoxylated sorbitan and sorbitol esters of fatty acids that function as surfactants in cosmetic formulations.<sup>2</sup> These ingredients were used in a total of 81 cosmetic formulations in 1998. The Polysorbates, which are food additives, were used in 1418 formulations. They are formed by the esterification of sorbitol or sorbitan with a fatty acid, followed by the chemical addition of ethylene oxide. Typical impurities can include the free fatty acids, alcohol, peroxides, isosorbide ethoxylates, and other compounds; 1,4-dioxane and other water-soluble by-products are removed during the manufacturing process.

Few data on the ingredients in this review were available; therefore, relevant data from the previous CIR safety assessments on the Polysorbates (other PEGs Sorbitan Fatty Acid Ester), PEGs, and Sorbitan Esters were included in this report as a further basis for assessing their safety in cosmetics.

During feeding studies, the Polysorbates were absorbed and hydrolyzed by blood and pancreatic lipases. The fatty acid moiety was absorbed and metabolized as any other dietary fatty acid, and the PEG Sorbitan moiety was excreted mainly in the urine. The gastrointestinal absorption of PEGs was dependent on the molecular weight; the greater the molecular weight, the lesser the absorption that occurs. In oral and IV studies, the PEGs were not metabolized and were rapidly eliminated in the feces and urine. PEGs were readily absorbed through damaged skin.

A number of cytotoxicity assays has been performed on the Polysorbates; they caused both membrane damage and reduced mitochondrial activity. A concentration of 5% PEG-20 Sorbitan Oleate in rats caused the "destruction" of the mitochondria of the epithelium of the small intestine of Wistar rats. The Polysorbate (concentration= 10%) caused a portion of the microvilli to disappear with flattening of the surfaces of the epithelial cells. PEG-20 Sorbitan Oleate had immunosuppressive effects in Balb/c mice that had been immunized with ovalbumin. PEG-20 Sorbitan Oleate was also a histamine-releasing agent, and increased recruitment of peritoneal macrophages without modifying phagocytic activity. PEG-20 Sorbitan Oleate (100 mg/ml) depressed cardiac potential in dogs and guinea pigs; the Polysorbate reduced mean arterial blood pressure and left ventricular dP/dt.

The Polysorbates had low toxicity in both acute and longterm toxicity studies using animals. In rats, the  $LD_{50}$  values for these ingredients were >5 to >38.9 g/kg (oral), ~1.4 g/kg (IV), and 0.7 to >5 ml/kg (IP). When administered to rats by IP injection, 16% PEG-20 Sorbitan Laurate and 32% PEG-20 Sorbitan Oleate decreased locomotor activity. During an inhalation toxicity study, PEG-20 Sorbitan Oleate (7%; 0.1 to 0.2 ml) was relatively nontoxic. The Sorbitan Esters and PEGs also were relatively nontoxic to animals.

During a 14-day feeding study of 3000 to 50,000 ppm PEG-20 Sorbitan Oleate, the high dose caused decreased body weight in male rats and mice, but no other clinical findings were reported. A vehicle containing 9% PEG-20 Sorbitan Oleate and 1% PEG-20 Sorbitan Laurate was mildly hepatotoxic to rabbits and, when given intraperitoneally, caused massive peritoneal fibrosis and degeneration of the kidneys in mice and rats. No adverse effects were observed in chicks fed 2% to 5% PEG-20 Sorbitan Stearate for 7 weeks. Rats fed 10% of the Polysorbate for 8 weeks had diarrhea for the first few days of treatment, but no other signs of toxicity. Rats fed 1.5 ml PEG-20 Sorbitan Oleate (1%-4%) for 3 months had congestive and degenerative changes in the heart, liver, and kidneys. In 6-week studies using rats and monkeys, PEG-4 Sorbitan Stearate, PEG-20 Sorbitan Stearate, and PEG-5 Sorbitan Oleate produced no significant adverse effects. In dermal toxicity studies, the PEGs did not cause signs of toxicity other than transient, mild erythema. Evidence of systemic toxicity was only observed in rabbits that received repeated topical applications of a PEG-based cream to abraded skin. Rats fed 1% to 4% Sorbitan Laurate for 6 weeks had decreased growth rates, and hamsters fed 15% for 68 days had degenerative changes of the gastrointestinal tract, and other lesions. Similar changes were observed in rats fed 25% Sorbitan Laurate for 70 days. Rhesus monkeys fed 2 g/day had no signs of toxicity after 6 weeks of treatment.

Growth retardation and diarrhea were noted in subchronic feeding studies of up to 1% PEG-20 Sorbitan Stearate using mice. Diarrhea in these and other studies was attributed to the high concentrations of the unabsorbed PEG Sorbitan moiety in the intestinal lumen. PEG-20 Sorbitan Oleate (up to 50,000 ppm) was nontoxic to rats and mice during a 13-week feed study. A concentration of 25% PEG-20 Sorbitan Laurate caused microscopic changes of the urinary bladder, spleen, kidneys, and gastrointestinal tract in rats during a 21-week study. The PEGs were nontoxic during a 90-day oral toxicity study using rats. Feeding of 10% to 25% Sorbitan Laurate for 90 days to 23 weeks caused decreased body and organ weights, diarrhea, and hepatic lesions in rats.

During a chronic toxicity study using hamsters, 5% to 15% PEG-20 Sorbitan Laurate caused microscopic lesions of the urinary bladder, kidneys, spleen, and gastrointestinal tract. In monkeys, 1 g/day PEG-20 Sorbitan Laurate did not cause adverse effects after 17 months of treatment. Rats fed up to 2% PEG-20 Sorbitan Laurate for over 2 years had no signs of toxicity. PEG-20 Sorbitan Stearate, PEG-20 Sorbitan Oleate, and PEG-20 Sorbitan Tristearate at concentrations <20% were nontoxic in long-term feeding studies using mice, rats, dogs, and hamsters. At concentrations of 20%, these Polysorbates caused some growth retardation and diarrhea, and had minor effects on longevity and reproduction. Studies using 2% PEG-20 Sorbitan Palmitate and PEG-20 Sorbitan Trioleate were also negative. In chronic studies, dogs fed 2% PEG-8, PEG-32, or PEG-75 for 1 year had no adverse effects; rats fed 5% Sorbitan Laurate for 2 years had no signs of toxicity, but only 15% of the treated and control rats survived to the end of the study.

The Polysorbates were nonirritating to mildly irritating in both in vivo and in vitro ocular irritation assays. The concentrations tested ranged from 1% to 100%. PEG-6 and PEG-75 did not cause corneal injuries when instilled into the conjunctival sac of rabbits, but 35% PEG-8 and 0.1 ml PEG-32 (melted in water bath) induced mild ocular irritation. Sorbitan Laurate (30%-100%) was not an ocular irritant in Draize ocular irritation tests using rabbits.

The Polysorbates had little potential for rabbit and mouse skin irritation in acute studies. Moderate to strong sensitization to PEG-20 Sorbitan Laurate was observed in a Magnusson Kligman guinea pig maximization test; PEG-20 Sorbitan Oleate and PEG-20 Tristearate were not sensitizers. PEG-20 Sorbitan Laurate (1%) did not have comedogenic potential in rabbits. The Sorbitan Esters were generally mild skin irritants, but did not cause sensitization in animals. The PEGs were neither irritants nor sensitizers.

In teratology studies of thalidomide, the PEG-20 Sorbitan Laurate vehicle (10 ml/kg) had no effect on the developing mouse embryo. In other studies, reproductive and developmental effects were seen primarily at exposure levels that were maternally toxic. PEG-20 Sorbitan Laurate caused dose-dependent malformations of offspring when administered to Swiss and NMRI mice via IP injections. In the Chernoff-Kavlock assay using Alpk/AP rats, 10 ml/kg/day PEG-20 Sorbitan Laurate reduced offspring litter size, survival, and weight gain when the Polysorbate was administered intraperitoneally, but the parameters did not differ from controls after dermal, oral, or subcutaneous administration. In another study using rats, PEG-20 Sorbitan Laurate had a maternal no-observable-effect level (NOEL) of 500 mg/kg/day, a maternal low effect level of 5000 mg/kg/day, and a developmental NOEL of > 5000 mg/kg/day.

PEG-20 Sorbitan Laurate, PEG-20 Sorbitan Palmitate, PEG-20 Sorbitan Stearate, and PEG-20 Sorbitan Oleate caused serious developmental effects in sea urchin embryos when administered at concentrations as low as 0.004% in sea water. Mice fed 10% PEG-20 Sorbitan Stearate or PEG-20 Sorbitan Laurate during a multigeneration study had offspring with decreased weanling weights, significantly smaller litters, and delivered more dead fetuses than mice of the control group. PEG-20 Sorbitan Oleate was not teratogenic in a rat whole-embryo culture study. In in vivo studies using neonatal rats, PEG-20 Sorbitan Oleate (1%-10%, IP injection) accelerated maturation, prolonged the estrous cycle, and induced chronic estrogenic stimulation. The ovaries were without corpora lutea and had degenerative follicles, and the uterus had epithelial squamous cell metaplasia and cytological changes. PEG-20 Sorbitan Oleate (2500 mg/kg/day in one study; 1.25 ml/l drinking water in another) and PEG-20 Sorbitan Stearate (0.1%-10% in one study; 5200 mg/kg/day in another) did not

cause developmental effects in rats and mice, but PEG-20 Sorbitan Oleate in drinking water increased locomotor activity and exploratory behavior of offspring of treated rats.

The PEG monomer, ethylene glycol, and certain of its monoalkyl ethers are reproductive and developmental toxins. The CIR Expert Panel concluded that, as the PEGs Sorbitan and Sorbitol Esters are chemically different from the alkyl ethers of ethylene glycol and the alkyl ethers are not present as impurities, these ingredients pose no reproductive or developmental hazard. In subchronic and chronic oral toxicity studies, the PEGs did not cause adverse reproductive effects.

The Polysorbates were nonmutagenic in a number of bacterial and mammalian systems, with the exception of PEG-20 Sorbitan Stearate, which produced both positive and negative results in genotoxicity assays.

In carcinogenicity studies, feeding of PEG-20 Sorbitan Oleate (up to 50,000 ppm) to rats and mice resulted in equivocal evidence of carcinogenicity; the male rats had an increased incidence of pheochromocytomas. The test compound was associated with inflammation and squamous hyperplasia of the nonglandular stomach in mice and with ulcers of the nonglandular stomach in female mice. PEG-20 Sorbitan Stearate did not increase the incidence of neoplasms in the nonglandular stomach and glandular stomach when administered with the carcinogens ENNG and MNNG. In general, the Polysorbates were not oral or dermal carcinogens, and were weak tumor promoters. PEG-20 Sorbitan Stearate and PEG-20 Sorbitan Oleate (0.002%) inhibited metabolic cooperation in V79 Chinese Hamster cells in vitro, which could result in tumor promotion. PEG-20 Sorbitan Stearate has been reported to have an in vivo promoter response, and the Polysorbate induced the cytoplasmic accumulation of proliferin transcripts in mouse fibroblasts; proliferin is an antagonistic regulator of musclespecific transcription, and can promote morphological transformation. The Polysorbates also had antitumor activity in animal studies. PEG-8 was noncarcinogenic in studies using mice, rats, and guinea pigs. Sorbitan Laurate and Sorbitan Stearate were also noncarcinogenic. At concentrations  $\geq$ 10%, Sorbitan Laurate was a tumor promoter in mouse skin.

The Polysorbates were nontoxic by the oral route in clinical studies, but a Polysorbate vehicle (9% PEG-20 Sorbitan Oleate, 1% PEG-20 Sorbitan Laurate) for a neonatal parenteral supplement caused the deaths of 38 premature infants. The symptoms and lesions observed included pulmonary deterioration, hepatomegaly, metabolic acidosis, and renal failure. Investigators concluded that human infant membranes were more sensitive to the effects of the Polysorbates and could not efficiently metabolize the compounds. Oleic acid and PEG moieties released during in vivo hydrolysis of PEG-20 Sorbitan Oleate could have contributed to the pulmonary deterioration and renal failure, as could ethylene glycol formed from ethylene oxide moieties.

The Polysorbates had little potential for human skin irritation, sensitization, and phototoxicity in extensive clinical studies. PEG-20 Sorbitan Oleate at a concentration of 100% was noncorrosive, and it and PEG-20 Sorbitan Laurate were not irritating to living skin equivalents. The PEGs were nonsensitizers, but cases of systemic toxicity and contact dermatitis were observed in burn patients that were treated with PEG-based topical ointments. The Sorbitan Esters had the potential to cause cutaneous irritation in humans, and could cause sensitization in patients with damaged skin. Sorbitan Stearate and Sorbitan Oleate were not photosensitizing; Sorbitan Laurate, Sorbitan Palmitate, Sorbitan Sesquioleate, and Sorbitan Trioleate did not absorb UVA or UVB light, suggesting that these compounds were not photosensitizers.

In clinical ocular irritation studies, PEG-20 Sorbitan Laurate was nonirritating, but at a concentration of 1%, it markedly increased the permeability of the corneal epithelium to fluorescein in the human eye. PEG-20 Sorbitan Oleate was classified as an ocular irritant, but further details were not available.

#### Sorbitan Beeswax, 2001

PEG-6, -8, and -20 Sorbitan Beeswax are ethoxylated derivatives of Beeswax that function as surfactants in cosmetic formulations.<sup>6</sup> In 1998, PEG-20 Sorbitan Beeswax was reported used in 16 cosmetic formulations; PEG-6 and -8 Sorbitan Beeswax were not reported used. Data submitted by industry indicated that PEG-20 Sorbitan Beeswax was used at concentrations from 0.2% in make-up fixatives to 11% in blushers. In 1984, it was reported used at concentrations  $\geq 10\%$ .

Few data were available on the PEGs Sorbitan Beeswax. Toxicology data on Beeswax, Synthetic Beeswax, Sorbitan Esters, PEGs, and Polysorbates were reviewed as a further basis for the assessment of safety.

The ester link of the Polysorbate (PEG Sorbitan Fatty Acid Ester) molecule was hydrolyzed by blood and pancreatic lipases after oral administration. The fatty acid moiety was absorbed and metabolized as any other dietary fatty acid, and the PEG Sorbitan moiety was poorly absorbed from the GI tract. GI absorption of PEG was inversely related to the molecular weight of the compound. PEGs are readily absorbed through damaged skin. Sorbitan Stearate was hydrolyzed to the stearic acid and anhydrides of sorbitol, and did not accumulate in the fat stores of the rat.

PEG-6 Sorbitan Beeswax was "practically nontoxic" when rats were treated with doses of 10.0 g/kg during acute IP studies. PEGs had low oral, dermal, and inhalation toxicity; greater molecular weight PEGs were less toxic than smaller molecular weight PEGs. The Polysorbates were not toxic during acute and long-term feeding studies, or during acute and short - term IV and IP injection studies. Formulations containing the Polysorbates produced no evidence of acute or subchronic percutaneous toxicity. Formulations containing up to 13% Beeswax (5 to 15 g/kg doses) were not toxic to rats. Undiluted Beeswax killed 2 of 10 rats within 2 days during an acute oral toxicity study. Ten rats fed 5 to 14.4 g/kg Synthetic Beeswax had chromorhinorrhea and chromodacryorrhea; rats fed 5 to 10.4 g/kg had diarrhea, ptosis, bulging eyes, and sniffling. Two rats died after ingestion of the high dose.

The Sorbitan Esters (<10%) were relatively nontoxic via ingestion. The lowest  $LD_{50}$  (rats) reported was 31 g/kg Sorbitan Stearate. No adverse effects were observed when rats, mice, and dogs were fed 5% Sorbitans Laurate, Oleate, and Stearate for up to 2 years. In other studies, the feeding of 0.5%, 4%, and 10% Sorbitan Stearate to mice and rats resulted in depressed growth and renal and/or hepatic abnormalities.

Undiluted PEG-6 Sorbitan Beeswax was nonirritating to the eyes of rabbits, and a 30% aqueous solution of PEG-20 Sorbitan Beeswax was minimally irritating (Draize score= 3.5/11 0). Eye makeup formulations containing 1.5% to 2.0% PEG-20 Sorbitan Beeswax were non- to minimally irritating to the eyes of rabbits. PEGs, Polysorbates, Sorbitan Esters, Beeswax, and Synthetic Beeswax were non- to mild ocular irritants. Undiluted PEG-6 Sorbitan Beeswax was nonirritating to the intact and abraded skin of rabbits. Cosmetic formulations containing 1.5% to 2.0% PEG-20 Sorbitan Beeswax were non- to minimal irritants to the skin of rabbits. The PEGs were not irritating to the skin of rabbits or guinea pigs, and PEG-75 was not a sensitizer. The Polysorbates had little potential for rabbit and mouse skin irritation during acute studies. Polysorbate 20 was a moderate to strong sensitizer in one study using guinea pigs, and Polysorbates 65 and 80 were nonsensitizers. Synthetic Beeswax (5 g in 1 ml corn oil) had Draize scores of 0 to 2.08 (out of 8.00) during primary irritation studies using rabbits. At a concentration of 50% in water, Synthetic Beeswax was nonsensitizing to guinea pigs. Sorbitan Esters (3% to 100%) were minimal to mild irritants.

Ethylene glycol and certain of its monoalkyl ethers are reproductive and developmental toxins. As PEGs Sorbitan Beeswax are chemically different from these ethers, reproductive and developmental toxicity due to the ethers was not of concern. PEGs did not cause adverse reproductive effects during subchronic and chronic feeding studies.

PEG-8 and -150 were not mutagenic in several genotoxicity assays. Polysorbate 80 was nonmutagenic in the Ames test. Sorbitan Stearate was not mutagenic in tests using bacteria, with or without metabolic activation, and did not transform hamster embryo cells in vitro. Sorbitan Oleate (0.01%) inhibited in vitro DNA repair. PEG-8 was not carcinogenic during oral, IP, or subcutaneous (SC) administration. The Polysorbates were generally noncarcinogenic, but enhanced the activity of some known chemical carcinogens. Sorbitan Stearate was not carcinogenic in mice during a feeding study, but Sorbitan Laurate was a tumor promoter during a mouse skin-painting study. Sorbitans Oleate and Trioleate were inactive as tumor promoters. In another study, undiluted Sorbitans Laurate and Trioleate were not cocarcinogens.

In clinical studies, PEG-6 and -20 Sorbitan Beeswax were nonsensitizers. Formulations containing up to 3.0% PEG-20 Sorbitan Beeswax were mildly irritating and nonsensitizing during in-use, minicumulative, and RIPTs. Systemic toxicity and contact dermatitis were observed in burn patients treated with PEG-containing ointments, but PEGs were not sensitizing to normal skin. The Polysorbates and Sorbitan Esters were nontoxic after oral ingestion. Polysorbates, Beeswax, and Synthetic Beeswax did not cause irritation, sensitization, or photosensitization. The Sorbitan Esters were minimal to mild skin irritants in humans, but were nonsensitizing, nonphototoxic, and nonphotoallergenic.

#### **CHEMISTRY**

#### **Definition and Method of Manufacture**

The ingredients in this report are polyethoxylated sorbitan or sorbitol esters of fatty acids. Each ingredient has a common core structure of sorbitan or sorbitol, etherified with PEG chains, and esterified with fatty acids (Figure 1). Sorbitan is related to sorbitol as the simple dehydration product.




Figure 1. Polysorbates, sorbitan ("polysorbate-#" or "PEG-x sorbitan nomenclature) and sorbitol ("sorbeth-#" nomenclature) derivatives.

While those ingredients with the nomenclature "polysorbate-#" form sorbitan by dehydration of sorbitol during the above reactions (which is consequently ethoxylated and esterified), those ingredients herein with the nomenclature "PEG-x sorbitan fatty ester" are the product of the ethoxylation of a preformed sorbitan ester. Regardless of the nomenclature, the ingredients under these two nomenclature schemes are related as polyethoxylated and esterified products of sorbitol. While these ingredients are predominately either sorbitan derivatives or sorbitol derivative, each may be mixtures resulting from some dehydration, isomerization, degree of ethoxylation, or degree of esterification. Accordingly, the ingredients in this report are closely related by like chemical structures and potential metabolism products (eg, via esterases know to be present in the skin).

Presented here are 2 possible routes for the synthesis of polysorbates.<sup>26</sup> In the first, sorbitol is esterified with fatty acids or their anhydrides, which is typically performed with acid catalysis at 130-180°C. At the temperature required for the esterification, water is eliminated from sorbitol to form 3 possible isomers of sorbitan and (with elimination of another water molecule) isosorbide. These dehydration products react with a fatty acid to form corresponding sorbitan esters. These products, which are known as "spans", are ethoxylated to produce polysorbates.

In the other common method of manufacture, sorbitol is reacted with ethylene oxide and a basic catalyst at 200-250°C. Under these conditions, sorbitol is isomerized as above. Addition of ethylene oxide yields ethoxylated products, which are called carbowaxes, and which are subsequently esterified with fatty acids to produce oligomers of polyoxyethylene sorbitan esters (aka polysorbates).

## **Chemical and Physical Properties**

Polysorbates (several of which are often referred to by the commercial trade name of Tween in the literature) are amphiphilic molecules, which are fatty esters of polyoxyethylated sorbitan or sorbitol.<sup>26</sup> The polysorbates are, for the most part, viscous liquids that range in color from yellow to orange to tan.<sup>1</sup> They possess a faint, characteristic odor and a warm, somewhat bitter taste (Table 3). The reported physical and chemical properties of generic sorbitan monolaurate, ethoxylated and sorbitan monostearate, ethoxylated are provided in Table 4.

Since the fatty acids used in the production of cosmetic ingredients frequently contain fatty acids other than the principal acid named (ie, a mixture), each of the polysorbates may contain a complex mixture of fatty acid moieties.<sup>1,27</sup> Table 5 provides an example of the approximate ester content of polysorbate 20, 21, 40, 60, and 80. Polysorbate 21 is reported to be 30%-80% monoesters, <50% diesters, and <20% triesters.<sup>23</sup> Sorbitan monolaurate is reported to be a mixture of esters of different lengths, with the highest percentage being C12, at 40%-60%.

#### Impurities

During the manufacturing process, the polysorbates are steam-stripped to remove unwanted water-soluble byproducts such as 1,4-dioxane.<sup>1</sup> Since PEGs are the condensation products of ethylene oxide and water, with the chain length controlled by the number of moles of ethylene oxide that are polymerized, they may contain trace amounts of 1,4-dioxane, a by-product of ethoxylation. 1,4-Dioxane is a known animal carcinogen.<sup>28</sup> The FDA has been periodically monitoring the levels of 1,4-dioxane in cosmetic products, and the cosmetic industry reported that it is aware that 1,4-dioxane may be an impurity in PEGs and, thus, uses additional purification steps to limit it in these ingredients before blending into cosmetic formulations.<sup>29,30</sup>

#### USE

#### Cosmetic

The Panel assesses the safety of cosmetic ingredients based on the expected use of these ingredients in cosmetics. The Panel reviews data received from the FDA and the cosmetics industry to determine the expected cosmetic use. The data received from the FDA are collected from manufacturers on the use of individual ingredients in cosmetics, by cosmetic product category, through the FDA Voluntary Cosmetic Registration Program (VCRP), and the data from the cosmetic industry are submitted in response to a survey of the maximum reported use concentrations, by category, conducted by the Personal Care Products Council (Council).

In 2015, the highest number of uses were reported for polysorbate 20 at 3013 (an increase from 770 in 1998), polysorbate 60 at 1589 (an increase from 332 in 1998), and polysorbate 80 at 932 (an increase from 231 in 1998).<sup>1,2,8</sup> Almost all of the previously reviewed ingredients had increases in the number of reported uses. All of the ingredients not previously reviewed had less than 15 reported uses (Tables 6 and 7).

A survey was conducted by the Council of the maximum use concentrations for ingredients in this group.<sup>31,32</sup> The highest concentrations of use were reported for polysorbate 20 at 19.6% in bath soaps and detergents (a decrease from >50% in 1984), polysorbate 80 at 18.1% in paste masks and mud packs (a decrease from up to 25% in 1984), polysorbate 81 at 25.6% in skin cleansing products (an increase from up to 5% in 1984), and polysorbate 85 at 21.9% skin cleansing products (a decrease from >50% in 1984).<sup>1,2,31</sup> The highest maximum concentration of use for leave-on products was 11.9% polysorbate 80 in perfumes.

In the 2000 published report, the only concentration of use data that were provided was the following: "...PEG-60 sorbitan tetraoleate, PEG-40 sorbitan tetraoleate, and PEG-160 sorbitan triisostearate are used in cosmetics at concentrations

of 0.5% to 10%...".<sup>2</sup> Since the data from the 2000 report are limited, the concentration of use data from the 1984 report were provided in Table 6 to give a better historical perspective.

PEG-18 sorbitan trioleate is no longer listed as a cosmetic ingredient in the *Dictionary*.<sup>4</sup> However, the VCRP reported 1 use in a moisturizer, which is a decrease from 10 uses reported in 1998.<sup>8</sup> The VCRP reported single uses for 3 other ingredients that are not listed in the *Dictionary*, PEG-20 sorbitan laurate (used in 1 other personal cleanliness product), PEG-20 sorbitan stearate (used in 1 night skin product), and PEG-30 sorbitan beeswax (used in 1 mascara). There were no concentrations of use reported for PEG-30 sorbitan beeswax.<sup>32</sup> No further information was found.

The 42 ingredients with no reported uses or concentrations of use are listed in Table 8.

All of the polysorbates named in this report, except Sorbeth-450 tristearate, are listed in the European Union inventory of cosmetic ingredients.<sup>33</sup>

In some cases, reports of uses were received in the VCRP, but no concentration of use data were available.<sup>8,31</sup> For example, PEG-3 sorbitan stearate was reported to be used in 3 formulations, but no use concentration data were reported. In other cases, no reported uses were received in the VCRP, however a use concentration was provided in the industry survey. For example, PEG-40 sorbitan laurate was not reported in the VCRP to be in use, but the industry survey indicated that it is used in leave-on formulations at up to 2% (skin care preparations) and rinse-off formulations up to 0.5% (shampoos and hair dyes and colors). It should be presumed that PEG-40 sorbitan laurate was used in at least 3 cosmetic formulations.

Several of these polysorbate ingredients are used in cosmetic products that may be ingested at up to 5.8%, in cosmetics used around the eyes at up to 11%, and in baby products at up to 12.6%.<sup>31,32</sup>

Polysorbates were reported to be used in cosmetic sprays, including aerosol and pump hair sprays, spray deodorants, spray body and hand products, and spray moisturizing products, and could possibly be inhaled. The highest concentration of use was reported to be polysorbate 20 in spray deodorants up to 4%. In practice, 95% to 99% of the droplets/particles released from cosmetic sprays have aerodynamic equivalent diameters >10  $\mu$ m, with propellant sprays yielding a greater fraction of droplets/particles below 10  $\mu$ m compared with pump sprays.<sup>34-37</sup> Therefore, most droplets/particles incidentally inhaled from cosmetic sprays would be deposited in the nasopharyngeal and bronchial regions and would not be respirable (ie, they would not enter the lungs) to any appreciable amount.<sup>34,36</sup> There is some evidence indicating that deodorant spray products can release substantially larger fractions of particulates having aerodynamic equivalent diameters in the range considered to be respirable.<sup>34</sup> However, the information is not sufficient to determine whether significantly greater lung exposures result from the use of deodorant sprays, compared to other cosmetic sprays.

#### **Non-Cosmetic**

The acceptable daily intake (ADI) for humans of polysorbates is 10 mg/kg.<sup>26</sup> The largest food sources of polysorbates are confectionery, ices, desserts, fine bakery wares, milk analogues, emulsified sauces, chewing gums, and fat emulsions for baking.

The polysorbates are used in the drug, food, and animal feed industries; several have been approved by the FDA as direct and indirect food additives for human consumption with certain restrictions (Table 9).

#### **TOXICOKINETICS**

Following oral administration of polysorbate 20 to rats, the ester bond sites of polysorbates are hydrolyzed within the digestive tract by pancreatic lipase.<sup>25</sup> Free fatty acids were absorbed from the digestive tract and oxidized and excreted, mainly as carbon dioxide in exhaled breath. No migration of the polyoxyethylene sorbitan into the thymus lymph nodes has been demonstrated. No sex difference has been detected in the disposition of polysorbates in rats.

Following oral ingestion of polysorbate 20 in humans, 90% or more of the administered substance was excreted in the feces as metabolites, with the polyoxyethylene sorbitan structure maintained, and 2%-3% of these metabolites were excreted in the urine.<sup>25</sup>

#### **Penetration Enhancement**

Polysorbate 20, polysorbate 65, and polysorbate 80 enhanced the dermal penetration of albuterol sulfate through rat skin using Franz cells (Table 10).<sup>38</sup>

## TOXICOLOGICAL STUDIES

Acute Toxicity

# Oral – Non-Human

**POLYSORBATE 81** 

The oral LD<sub>50</sub> of polysorbate 81 was reported to be > 20 000 mg/kg for rats (n=11).<sup>24</sup>

# Oral - Human

#### SORBITAN MONOSTEARATE, ETHOXYLATED

No toxic effects were observed in human subjects (n=6) orally administered sorbitan monstearate, ethoxylated (20g).<sup>25</sup> The amount of gastric acid was slightly reduced. It was concluded that sorbitan monostearate, ethoxylated was not orally toxic to humans.

## Dermal – Non-Human

#### SORBITAN MONOSTEARATE, ETHOXYLATED

The acute dermal  $LD_{50}$  of sorbitan monostearate, ethoxylated in Wistar albino rats (n=10/sex) was reported to be >2000 mg/kg.<sup>25</sup>

#### Inhalation – Non-Human

#### SORBITAN MONOLARUATE, ETHOXYLATED

The inhalation  $LC_{50}$  was reported to be 5.1 mg/L air for sorbitan monolaurate, ethoxylated administered to Crl:Wl(Han) rats (n=5) for 4 h in a nose-only apparatus.<sup>23</sup> No clinical signs of systemic toxicity were observed up to the end of the 14-day observation period. No abnormalities were observed at macroscopic post mortem examination of the animals.

#### Intravenous – Non-Human

POLYSORBATE 20

The intravenous  $LD_{50}$  for polysorbate 20 in mice was reported to be 1420 mg/kg.<sup>23</sup>

#### **Repeated Dose Toxicity**

In a survey of 4 laboratories of the historical use of vehicles for in vivo experiments, the highest no-observedadverse-effect levels (NOAEL) of various routes of administration were assembled.<sup>39</sup> The highest oral NOAELs for polysorbate 20 were 250 and 500 mg/kg/d for 1 month and 90 days in rats, respectively, and 10 mg/kg/d for 1 month in mice (Table 11). For polysorbate 80, the highest oral NOAEL for 90 days in dogs was 5 mL/kg/d, and for 4 weeks in rats was 5 mL/kg/d. The NOAEL for intranasal administration of polysorbates 80 for 3 days to mice was 10  $\mu$ L/nostril/d at 0.2%.

#### Oral – Non-Human

## **POLYSORBATE 20**

In a 22-month feeding study, the NOAEL of polysorbate 20 in male C57BL/6 Jax mice was 114285.71 mg/kg/d (10% in feed).<sup>25</sup> Decreased hematologic values were observed but not specified. No characteristic morphologic anemia was observed. The feed contained 5% or 10% polysorbate 20. No further details were provided.

#### POLYSORBATE 80

There were no adverse effects or mortalities related to polysorbate 80 (0.005, 0.05, or 0.15 g/kg/d) when administered by gavage to Sprague-Dawley rats (n=5) for 5 days.<sup>40</sup> There were no clinical signs and no significant findings at necropsy. There were decreased serum glucose and increased serum sodium at all concentrations, as well as decreases in uric acid in the mid- and high-dose groups. The high-dose group exhibited a modest reduction in serum calcium levels.

There were no adverse effects or mortalities reported when Sprague-Dawley rats (n=6/sex) were orally administered polysorbate 80 (148, 740, or 3700 mg/kg/d in saline) for 28 days after 28 days of a high fat diet.<sup>41</sup> It was not clear if the rats continued on the high fat diet during treatment with polysorbate 80.

In the same study, there were no adverse effects or mortalities reported when C57BL/6J mice (n=6/sex) were orally administered polysorbates 80 (400, 1600, or 6400 mg/kg/d in saline) for 28 days after 28 days of a high fat diet. In additional studies, there were no adverse effects or mortalities reported when the same strain of mice (n=5/sex) were orally administered polysorbate 20, polysorbate 40, or polysorbate 60 (1600 mg/kg/d in saline) for 28 days also after 28 days of a high fat diet. It was not clear if the rats continued on the high fat diet during treatment with the polysorbates.<sup>41</sup>

## **REPRODUCTIVE AND DEVELOPMENTAL TOXICITY**

#### POLYSORBATE 60

The teratogenic and reproductive NOAEL was reported to be 7693 mg/kg/d when polysorbate 60 (0, 0.1%, 1.0% or 10% in feed; 0, 99 mg/kg, 960 mg/kg, 7693 mg/kg) was administered to pregnant Wistar rats on gestations days 7-14.<sup>25</sup> There were no effects by polysorbate 60 on the number, sex ratio and body weights of live fetuses. There were no differences between the polysorbate 60-treated and control groups observed in the numbers of resorptions, dead fetuses and live fetuses per litter, the sex ratio of live fetuses, and the fetal body weight of both sexes. External, skeletal, and internal examinations of the fetuses revealed no evidence of teratogenesis. It was concluded that polysorbate 60 had no harmful effects on the prenatal development of the rat offspring.

#### POLYSORBATE 80

In a reproductive and developmental study where polysorbate 80 (500 and 5000 mg/kg/d in distilled water; 5 mL) was administered by gavage to Crl:CD BR VAF/PlusTM outbred albino rats (n=25) on gestation days 6-15, the maternal and the developmental NOAELs were reported to be >5000 mg/kg/d.<sup>24</sup> The control group was administered 5 mL/kg distilled water. No maternal mortalities or treatment-related clinical signs of toxicity were observed. No effects on weight gain, organ weights (except non-adverse increased relative liver weights), and feed and water consumption. There were no differences in the number of corpora lutea per dam, number of implantations per litter, percent preimplantation loss per litter,

percent resorptions per litter, and percent litters with resorptions. No adverse fetal effects were observed, including growth, viability, or development of the fetuses. There were no observed differences in malformations between treatment groups and controls.<sup>24</sup>

## GENOTOXICITY In Vitro

#### POLYSORBATE 20

After conducting the series of assays of the cyto/genotoxicity of polysorbate 20 below, the authors concluded that this ingredient can induce apoptosis in human umbilical vein endothelial cells (HUVEC) and A549 lung cancer cells.<sup>42</sup> The authors stated that when the following assays are considered together, they show that polysorbate 20 can interact with DNA in treated cells to cause DNA damage and fragmentation. Therefore, they concluded that polysorbate 20 inhibits the growth of both normal and cancer cell lines by inducing apoptosis via chromatin and DNA fragmentation.

In an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay, there was a dose- and timedependent reduction in cell growth for both the HUVEC and A549 cells with IC<sub>50</sub>s of approximately 0.3 and 0.4  $\mu$ L/mL polysorbate 20, respectively. There was >90% cell death observed after treatment with 2  $\mu$ L/mL, and the greatest cell death was observed in the highest test group. For the assay, the cells were incubated in the various concentrations of polysorbate 20 (2, 4, 6, 8, or 10  $\mu$ L/mL) for 24, 48, and 72 h, and then washed.

In a DAPI (4',6-diamidino-2-phenylindole) staining assay, morphological changes and fragmentation in the chromatin and DNA rings within the nucleus were observed in the polysorbate-treated cells of both cell lines, but morphology was unaltered in untreated cells. Polysorbate 20-treated cells showed chromatin and DNA fragmentation as high as the positive control of 5% dimethyl sulfoxide (DMSO). For the assay, the cells were treated with polysorbates 20 (4  $\mu$ L/mL) for various durations (not provided), then fixed and stained with DAPI.

In a DNA fragmentation assay analyzed by agarose gel electrophoresis, polysorbate 20 (concentration not clear) induced apoptosis by DNA fragmentation after incubation for 24 h. The gel showed the formation of DNA ladders of both treated cell lines.

An alkaline comet assay showed that polysorbate 20 (2  $\mu$ L/mL)-treated A549 cells exhibited increased DNA cleavages compared to untreated cells and similar DNA cleavages to the positive control, hydrogen peroxide (200 mM)-treated cells. Only A549 cells were used in this assay; HUVEC cells were not used.

When polysorbate 20 (2  $\mu$ L/mL)-treated A549 cells were analyzed with a fluorescein isothiocyanate (FITC)-labeled annexin V apoptosis assay and flow cytometry analysis was used to estimate early and late apoptosis, the results were similar to the results of the DAPI staining assay. Almost all of the treated cells were in early and late stages of apoptosis after 24 h; less than half of DMSO-treated control cells were in early and late stages of apoptosis for the same period of exposure. Only A549 cells were used in this assay; HUVEC cells were not used.<sup>42</sup>

## POLYSORBATE 80

Polysorbate 80 was not genotoxic to *Salmonella typhimurium* (strains TA98, TA100, TA1535, and TA1537) at up to  $10\,000\,\mu$ g/plate (in distilled water) with and without metabolic activation.<sup>24</sup> The controls had the expected results.

Polysorbate 80 was not genotoxic to *S. typhimurium* (strains TA1535, TA1537, TA98 and TA100) and *Escherichia coli* (strain WP2 uvr A) at up to 5000  $\mu$ g/plate (in ethanol) with and without metabolic activation.<sup>24</sup> The controls had the expected results.

#### SORBITAN MONOLAURATE, ETHOXYLATED

Sorbitan monolaurate, ethoxylated was not mutagenic, with or without metabolic activation, in an Ames assay using *S. typhimurium* (strains TA1535, TA1537, TA98, and TA100) and *E. coli* (strain WP2 uvr A) in 3 separate experiments.<sup>23</sup> In experiment 1, *S. typhimurium* (strains TA1535, TA1537, TA98) was tested at 10-3330 µg/plate in ethanol; and *S. typhimurium* (strain TA100) and *E. coli* were also tested at 3 and 5000 µg/plate with and without metabolic activation. In experiment 2, *S. typhimurium* (strains TA1535 and TA98) was tested at 33-5000 µg/plate in ethanol with and without metabolic activation. In experiment 3, all strains were tested again at 33-5000 µg/plate in ethanol with and without metabolic activation. Controls had the expected results.

In a chromosomal aberration assay using human lymphocytes, sorbitan monolaurate, ethoxylated was not genotoxic up to  $100 \,\mu$ g/mL in ethanol, with and without metabolic activation, but was cytotoxic at  $300 \,\mu$ g/mL.<sup>23</sup> Assays were run for 3, 24 and 48h. Controls had the expected results.

In 2 mammalian cell gene mutation assays using mouse lymphoma L5178Y cells, sorbitan monolaurate, ethoxylated was not found to be genotoxic.<sup>23</sup> In the first experiment, the cells were tested for 3 h at 0.3-275  $\mu$ g/mL without metabolic activation and at 0.3-300  $\mu$ g/mL with metabolic activation in ethanol. In the second experiment, the cells were tested for 3 h at: 0.3-150  $\mu$ g/mL without metabolic activation and at 0.3-350  $\mu$ g/mL with metabolic activation in ethanol. Controls had the expected results.

## SORBITAN MONOOLEATE, ETHOXYLATED

Sorbitan monooleate, ethoxylated produced ambiguous results in a chromosome aberration assay using Chinese hamster ovary (CHO; CHO-W-B1) cells.<sup>24</sup> The number and percentages of aberrations did not change in a concentration-dependent manner. Sorbitan monooleate, ethoxylated was tested at 300-1600  $\mu$ g/mL without metabolic activation and 100-1000  $\mu$ g/mL in DMSO. The positive controls were mitomycin and cyclophosphamide, which had the expected results.

Sorbitan monooleate, ethoxylated was not genotoxic in a chromosome aberration assay using CHO (CHO-W-B1) cells.<sup>43</sup> Sorbitan monooleate, ethoxylated was tested at 300-1600  $\mu$ g/mL without metabolic activation and 16-500  $\mu$ g/mL in DMSO. The positive controls were mitomycin and cyclophosphamide. The controls had the expected results.

#### SORBITAN MONOSTEARATE, ETHOXYLATED

Sorbitan monostearate, ethoxylated (concentration and vehicle were not specified) was not mutagenic in a bacterial gene mutation assay using *S. typhimurium* (strain TA 98) with metabolic activation.<sup>25</sup>

## CARCINOGENICITY

No new carcinogenicity data on polysorbates were found in the published literature nor were unpublished data provided.

## IRRITATION AND SENSITIZATION Irritation

#### Dermal – Non-Human

POLYSORBATE 60

In a daily skin-painting study of polysorbate 60 (5% aqueous) on rabbits for 30 days, there was moderate irritation observed; skin necrosis occurred when a 10% solution was tested.<sup>25</sup> In a further study on rabbits, there were no dermal effects from a 15% aqueous solution administered for 60 consecutive days; there was mild irritation after administration of an undiluted solution. Local inflammation also occurred after long-term (time not specified) administration of an undiluted polysorbate 60 solution to mouse skin (n not specified).

#### SORBITAN MONOLAURATE, ETHOXYLATED

Sorbitan monolaurate, ethoxylated (100%; 0.5mL) had a Draize score of 0.89 out of 4 when administered to New Zealand White rabbits (n=3) for 4 h under occlusion.<sup>23</sup> Scaliness was observed in all 3 animals at 72 h after exposure and in 1 rabbit at 7 days after exposure. The test sites were observed at 1, 24, 48, and 72 h and 7 days. An untreated site on each rabbit served as the control.

#### SORBITAN MONOSTEARATE, ETHOXYLATED

When sorbitan monostearate, ethoxylated (5% and 10% aqueous) was dermally administered to rabbits (n not specified) for 30 days, the test substance caused necrosis of the skin at 10%.<sup>25</sup> The necrosis was reversible after stopping treatment. Moderate irritation was observed at 5%.

Administration of sorbitan monostearate, ethoxylated (100%) for 60 days did not cause irritation in rabbits.<sup>25</sup> No further information was provided.

Sorbitan monostearate, ethoxylated (100%; 0.5 g) did not produce any skin reaction when administered to the shaved backs (approximately  $6 \text{ cm}^2$ ) of New Zealand white rabbits (n=3).<sup>25</sup> The irritation score was 0.8 out of 8. The test substance was administered under occlusion for 4 h; the test site was observed for 14 days after removal.

#### Dermal – Human

In human irritation studies, polysorbate 60 (100%), polysorbate 80 (100%), and sorbitan monostearate, ethoxylated (25%) were not dermally irritating (Table 12).<sup>25,44-46</sup>

#### Ocular – Non-Human

Tests of polysorbate 20 (up to 10%) and polysorbate 81 (up to 100%) showed that these ingredients were not ocular irritants in rabbits (Table 13).<sup>47-49</sup> Sorbitan monostearate, ethoxylated (0.1 g in water) and sorbitan monolaurate, ethoxylated (100%; 0.1 mL) were not ocular irritants to rabbits.<sup>23,24</sup>

#### Ocular – In Vitro

## POLYSORBATE 20

In vitro ocular irritation tests of polysorbate 20 had mixed results. EpiOcular tests, a red blood cell hemolysis assay, and a k562 cell assay predicted polysorbate 20 to be a non- or minimal ocular irritant at 2% and 100% (Table 13).<sup>50,51</sup> Polysorbate 20 was predicted to be an ocular irritant in a short time exposure (STE) assay using SIRC cells, Hen's Egg test-Chorioallantoic Membrane (HET-CAM) assays, and Bovine Corneal Opacity and Permeability (BCOP) assay.<sup>50</sup>

#### Sensitization

## Non-Human

# POLYSORBATE 81

Polysorbate 81 (2% and 4% in corn oil) was not sensitizing to female Dunkin-Hartley guinea pigs (n=10) when the guinea pigs were challenged 21 days after last induction at 100% (0.5 mL).<sup>23,24</sup> There were no signs of sensitization up to 72 h after the challenge. The positive control,  $\alpha$ -hexyl cinnamic acid (20%), had the expected results.

## SORBITAN MONOLAURATES, ETHOXYLATED

In a local lymph node assay, using female CBA mice (n=5), of sorbitan monolaurates, ethoxylated (25%, 50% and 100% in acetone/olive oil [4:1 v/v]; 25  $\mu$ L), the stimulation indexes (SI) were calculated to be 1.9, 6.0 and 5.0, respectively. The test substance was considered sensitizing.<sup>23</sup> The authors noted that the response of the 100% group did not follow the expected dose-response relationship, which they also noted was common in this kind of study. The response might be less due to differences in skin penetration (no vehicle present) or viscosity. The estimated concentration of polysorbates that would give an SI of 3 was calculated to be 34%. The positive control, hexyl cinnamic aldehyde, had the expected results.

## Human

## POLYSORBATE 81

In a human patch test (n=50), polysorbate 81 (100%) was not sensitizing.<sup>24</sup> There were no signs of irritation or sensitization observed in any subject. The test material was administered under occlusion for 3 days. After 7 days, challenge patches were administered for 72 h.

In a human patch test (n=10), polysorbate 81 (100%) was not sensitizing.<sup>24</sup> There were no signs of irritation or sensitization observed in any subject. The test material was administered under occlusion for 5 days. After 10 days, challenge patches were administered for 48 h.

In a human patch test (n=10), polysorbate 81 (12%; vehicle not specified) was not sensitizing.<sup>24</sup> There were no signs of irritation or sensitization observed in any subject. The test material was administered under occlusion for 5 days. After 10 days, challenge patches were administered for 48 h.

## SUMMARY OF NEW DATA

This is a re-review of the safety of polysorbates as used in cosmetics. Safety assessments of various polysorbates were published in 1984, 2000, and 2001 with conclusions of safe as used. These safety assessments have been combined, and additional polysorbate ingredients have been identified and included, in this assessment for a total of 82 ingredients. All of these polysorbate ingredients are related in that they have a common core structure of sorbitan or sorbitol etherified with PEG chains.

The highest number of uses were reported for polysorbate 20 at 3013 (an increase from 770 in 1998), polysorbate 60 at 1589 (an increase from 332 in 1998), and polysorbates 80 at 932 (an increase from 231 in 1998). Almost all of the previously reviewed ingredients had increases in the number of reported uses. The highest maximum concentrations of use were reported for polysorbate 20 at 19.6% (a decrease from >50% in 1984), polysorbate 80 at 18.1% (a decrease from up to 25% in 1984), polysorbate 81 at 25.6% (an increase from up to 5% in 1984), and polysorbate 85 at 21.9% (a decrease from >50% in 1984) in rinse-off products. The highest maximum concentration of use for leave-on products was 11.9% polysorbate 80 in perfumes.

Polysorbate 20, polysorbate 65, and polysorbate 80 enhanced the dermal penetration of albuterol sulfate through rat skin.

The oral LD<sub>50</sub> of polysorbate 81 was reported to be > 20 000 mg/kg for rats. The acute dermal LD<sub>50</sub> of sorbitan monostearate, ethoxylated in rats was reported to be >2000 mg/kg. The inhalation LC<sub>50</sub> was reported to be 5.1 mg/L air for sorbitan monolaurate, ethoxylated administered to rats for 4 h. The intravenous LD<sub>50</sub> for mice was reported to be 1420 mg/kg.

There were no adverse effects or mortalities related to polysorbate 80 (up to 0.15 g/kg) when administered by gavage to rats for 5 days or in rats orally administered polysorbate 80 (up to 3700 mg/kg/d) for 28 days. There were no adverse effects observed in mice orally administered polysorbate 80 (up to 6400 mg/kg/d), or polysorbate 20, polysorbate 40, or polysorbate 60 (1600 mg/kg/d) for 28 days.

The teratogenic and reproductive NOAEL of polysorbate 60 was reported to be 7693 mg/kg/d (ie, the highest dose tested) when administered to pregnant rats on gestations days 7-14 in feed. In a reproductive and developmental study where polysorbate 80 was administered by gavage to rats on gestation days 6-15, the maternal and the developmental NOAELs were reported to be >5000 mg/kg/d.

Polysorbate 80 was not genotoxic to S. typhimurium, up to  $10\,000\,\mu$ g/plate, and E. coli, up to  $5000\,\mu$ g/plate, with and without metabolic activation

The combined results of MTT, DAPI, DNA fragmentation, alkaline comet, and FITC-labeled annexin V apoptosis assays led to the conclusion that polysorbate 20 had the capability of interaction with DNA in treated HUVEC and A549 lung cancer cells that resulted in DNA damage and fragmentation. It was concluded that polysorbates 20 inhibits the growth of both normal and cancer cell lines by inducing apoptosis via chromatin and DNA fragmentation.

In a 30-day skin-painting study of polysorbate 60 in rabbits, there was moderate irritation observed at 5% and skin necrosis at10%. In a study in rabbits, there were no dermal effects from a 15% aqueous solution of polysorbate 60 administered for 60 consecutive days; there was mild irritation after administration of an undiluted solution. Local inflammation also occurred after long-term (time not specified) administration of an undiluted polysorbate 60 solution to mouse skin

In a clinical test, polysorbate 60 at 100%, polysorbate 80 at 100%, and sorbitan monostearate, ethoxylated at 25% were not dermally irritating.

In vivo tests of polysorbate 20 (up to 10%) and polysorbate 81 (up to 100%) showed these ingredients not to be ocular irritants. In vitro predictions tests had mixed results. EpiOcular tests, a red blood cell hemolysis assay, and a k562 cell assay predicted that polysorbate 20 to be a non- or minimal ocular irritant at 2% and 100%. STE at 5%, HET-CAM at 100%, and BCOP at 100% predicted that polysorbate 20 would be a mild to severe ocular irritant.

Polysorbate 81 up to 4% was not sensitizing to guinea pigs when challenged 21 days after last induction at 100%. Polysorbate 81 at 100% was not sensitizing in human patch tests.

#### **DISCUSSION**

This is a re-review of polysorbates from 3 previous safety assessments that have been combined, along with similar polysorbates that have not been reviewed, into one report. The Panel agreed that grouping these ingredients together was appropriate because of the common core structure of sorbitan or sorbitol, etherified with PEG chains, and esterified with fatty acids.

The CIR Expert Panel recognizes that there are data gaps regarding use and concentration of these ingredients. However, the overall information available on the types of products in which these ingredients are used, concentrations of use and the similar pattern of use raise little safety concerns.

The Panel cautioned that polysorbate 20, polysorbate 65, and polysorbate 80 can enhance drug absorption. The Panel cautions that care should be taken in formulating cosmetic products that may contain these ingredients in combination with any ingredients whose safety was based on their lack of dermal absorption data, or when dermal absorption was a concern. Especially, care should be taken when creating formulations especially those products intended for use on infants.

To address the possible presence of 1,4-dioxane and ethylene oxide impurities in these ingredients, the Panel stressed that the cosmetics industry should continue to use the necessary procedures to limit these impurities from the PEG ingredients before blending them into cosmetic formulations.

The Panel expressed concern about pesticide residues and heavy metals that may be present in botanical (ie, coconut-derived) ingredients. They stressed that the cosmetics industry should continue to use current good manufacturing practices (cGMPs) to limit impurities.

Data from the 1984 safety assessment suggested that polysorbates caused a slight enhancement of tumor development caused by 7, 12-dimethyl-benz[a]antracene (DMBA) and *N*-methyl-*N*'-nitro-*N*-nitrosoquanidine (MNNG). However the data were not consistent. For other compounds, the tumorigenic properties of 3-methyl-chloanthrene (MCA) and 3,4-benz[a]-pyrene (BP) were not enhanced by polysorbates. Overall, since tumor enhancement was not consistently demonstrated, the Panel was not concerned.

Because some studies showed minimal irritation at concentrations that are used in cosmetics, the Panel cautioned that products containing these ingredients should be formulated to be non-irritating.

It was noted that at the time of the 2001 safety assessment on the sorbeth beeswaxes, the Panel had recommended that cosmetic formulations containing PEGs not be used on damaged skin. Since then, PEGs have been re-reviewed and the Panel has removed the caveat that PEGs should not be used on damaged skin.

The Panel discussed the issue of incidental inhalation exposure from including aerosol and pump hair sprays, spray deodorants, spray body and hand products, and spray moisturizing products. The limited acute exposure data available from 1 inhalation study suggest little potential for respiratory effects at relevant doses. The Expert Panel believes that the sizes of a substantial majority of the particles of these ingredients, as manufactured, are larger than the respirable range and/or aggregate and agglomerate to form much larger particles in formulation. These ingredients are reportedly used at concentrations up to 4% in cosmetic products that may be aerosolized. The Panel noted that 95% – 99% of droplets/particles would not be respirable to any appreciable amount. Coupled with the small actual exposure in the breathing zone and the concentrations at which the ingredients are used, the available information indicates that incidental inhalation would not be a significant route of exposure that might lead to local respiratory or systemic effects. The Panel considered other data available to characterize the potential for polysorbates to cause systemic toxicity, irritation, sensitization, reproductive and developmental toxicity, and genotoxicity. They noted the lack of systemic toxicity at low and moderate doses in several acute and repeated dose oral exposure studies and low toxicity at high does; little or no irritation or sensitization in multiple tests of dermal and ocular exposure; the absence of genotoxicity in multiple Ames tests and chromosome aberration tests, and minimal irritation and lack of sensitization in tests of dermal exposure at concentration of use. A detailed discussion and summary of the Panel's approach to evaluating incidental inhalation exposures to ingredients in cosmetic products is available at http://www.cir-safety.org/cir-findings.

## **CONCLUSION**

The CIR Expert Panel concluded that polysorbates are safe in cosmetics when formulated to be non-irritating. This conclusion supersedes the conclusion reached in the 1984, 2000, and 2001 safety assessments.

Polysorbate 20 Polysorbate 21 Polysorbate 40 Polysorbate 60 Polysorbate 61 Polysorbate 65 Polysorbate 80 Polysorbate 81 Polysorbate 85 PEG-30 sorbitan beeswax PEG-20 sorbitan cocoate PEG-40 sorbitan diisostearate PEG-2 sorbitan isostearate\* PEG-5 sorbitan isostearate\* PEG-20 sorbitan isostearate PEG-40 sorbitan lanolate PEG-75 sorbitan lanolate\* PEG-10 sorbitan laurate PEG-20 sorbitan laurate PEG-40 sorbitan laurate PEG-44 sorbitan laurate PEG-75 sorbitan laurate PEG-80 sorbitan laurate PEG-3 sorbitan oleate PEG-6 sorbitan oleate PEG-20 sorbitan oleate\* PEG-40 sorbitan oleate\* PEG-80 sorbitan palmitate\* PEG-40 sorbitan perisostearate\* PEG-40 sorbitan peroleate PEG-3 sorbitan stearate PEG-4 sorbitan stearate\* PEG-6 sorbitan stearate PEG-20 sorbitan stearate PEG-40 sorbitan stearate PEG-60 sorbitan stearate\* PEG-30 sorbitan tetraoleate PEG-40 sorbitan tetraoleate PEG-60 sorbitan tetraoleate PEG-60 sorbitan tetrastearate\* PEG-4 sorbitan triisostearate\*

PEG-20 sorbitan triisostearate\* PEG-160 sorbitan triisostearate PEG-2 sorbitan trioleate\* PEG-18 sorbitan trioleate PEG-3 sorbitan tristearate\* Sorbeth-2 beeswax\* Sorbeth-6 beeswax Sorbeth-8 beeswax\* Sorbeth-20 beeswax Sorbeth-2 cocoate\* Sorbeth-2 hexacaprylate/caprate\* Sorbeth-12 hexacocoate\* Sorbeth-2 hexaisostearate\* Sorbeth-2 hexalaurate\* Sorbeth-2 hexaoleate\* Sorbeth-40 hexaoleate\* Sorbeth-50 hexaoleate\* Sorbeth-6 hexastearate\* Sorbeth-150 hexastearate\* Sorbeth-3 isostearate\* Sorbeth-6 laurate\* Sorbeth-2/oleate/dimer dilinoleate crosspolymer\* Sorbeth-20 pentaisostearate\* Sorbeth-30 pentaisostearate\* Sorbeth-40 pentaisostearate\* Sorbeth-50 pentaisostearate\* Sorbeth-40 pentaoleate\* Sorbeth-20 tetraisostearate\* Sorbeth-30 tetraisostearate Sorbeth-40 tetraisostearate\* Sorbeth-50 tetraisostearate\* Sorbeth-4 tetraoleate Sorbeth-6 tetraoleate Sorbeth-30 tetraoleate Sorbeth-40 tetraoleate Sorbeth-60 tetraoleate Sorbeth-30 tetraoleate laurate\* Sorbeth-60 tetrastearate\* Sorbeth-3 tristearate\* Sorbeth-160 tristearate\* Sorbeth-450 tristearate\*

\*Not reported to be in current use. Were ingredients in this group not in current use to be used in the future, the expectation is that they would be used in product categories and at concentrations comparable to others in this group.

## TABLES AND FIGURES

Table 1.	The Definitions and Functions of the Polysorbates in This Safety Assessment. <sup>4</sup>
	[Bracketed entries are the work product of CIR staff]





 Table 1. The Definitions and Functions of the Polysorbates in This Safety Assessment.<sup>4</sup>

 [Bracketed entries are the work product of CIR staff]



**Table 1.** The Definitions and Functions of the Polysorbates in This Safety Assessment.<sup>4</sup>[Bracketed entries are the work product of CIR staff]





 Table 1. The Definitions and Functions of the Polysorbates in This Safety Assessment.<sup>4</sup>

 [Bracketed entries are the work product of CIR staff]



**Table 1.** The Definitions and Functions of the Polysorbates in This Safety Assessment.<sup>4</sup>[Bracketed entries are the work product of CIR staff]





 Table 1. The Definitions and Functions of the Polysorbates in This Safety Assessment.<sup>4</sup>

 [Bracketed entries are the work product of CIR staff]



**Table 1.** The Definitions and Functions of the Polysorbates in This Safety Assessment.<sup>4</sup>

 [Bracketed entries are the work product of CIR staff]






 Table 1. The Definitions and Functions of the Polysorbates in This Safety Assessment.<sup>4</sup>

 [Bracketed entries are the work product of CIR staff]



**Table 1.** The Definitions and Functions of the Polysorbates in This Safety Assessment.<sup>4</sup>[Bracketed entries are the work product of CIR staff]



Ingredient and CAS No.	Definition	Function
Polysorbate Tetraesters		
Sorbitan Derivatives PEG-60 sorbitan tetrastearate	The tetraester of stearic acid and a polyethylene glycol ether of sorbitol, with an average of 60 moles of ethylene oxide.	Surfactant- emulsifying agent
	$H_{3}C_{(CH_{2}CH_{2}CH_{2})_{w}} O_{(CH_{2}CH_{2}O)_{w}} O_{(CH_{2}CH_{2}O)$	
PEG-30 sorbitan tetraoleate	(one example of a tetraester) where $w + x + y + z$ has an average value of 60. The tetraester of oleic acid and a polyethylene glycol ether of sorbitol, with an average of 30 moles of ethylene oxide.	Surfactant- emulsifying agent
	$H_{3}C_{(CH_{2})_{7}}(CH_{2}CH_{2})_{4}}(CH_{2}CH_{2})_{4}}(CH_{2}CH_{2})_{4}}(CH_{2}CH_{2}O)_{5}}(CH_{2}O)_{5}}$	
PEG-40 sorbitan tetraoleate	The tetraester of oleic acid and a polyethylene glycol ether of sorbitol, with an average of 40 moles of ethylene oxide.	Surfactant- emulsifying agent
	$H_{3}C (CH_{2})_{7} (CH_{2}CH_{2})_{8} (CH_{2}CH_{2})_{8} (CH_{2}CH_{2})_{7} (CH_{2}CH_{2})_{7} (CH_{2}CH_{2})_{7} (CH_{2}CH_{2})_{7} (CH_{2})_{7} (CH_{2})_{7}$	
PEG-60 sorbitan tetraoleate	The tetraester of oleic acid and a polyethylene glycol ether of sorbitol, with an average of 60 moles of ethylene oxide.	Surfactant- emulsifying agent
	$H_{3}C (CH_{2})_{7} (CH_{2})_{7} (CH_{2}CH_{2})_{8} (CH_{2}CH_{2})_{7} (CH_{2})_{7} (CH_{2})_{$	
<b>Polysorbate Esters - mi</b> Sorbitan Derivatives	xtures	
PEG-40 sorbitan perisostearate	A mixture of isostearic acid esters of sorbitol condensed with an average of 40 moles of ethylene oxide.	Surfactant- emulsifying agent
	$H_3C$ $(CH_2CH_2C)_{1/4}$ $(OCH_2CH_2)_{1/4}$ $(OCH_2CH_2)_{1/4}$ $(OCH_2CH_2C)_{2/3}$ $(CH_2CH_2C)_{2/3}$ $(CH_2CH_2C)_{2/3}$	
	wherein each R is hydrogen or isostearate, and w+x+y+z has an average value of 40.	

**Table 1.** The Definitions and Functions of the Polysorbates in This Safety Assessment.<sup>4</sup>

 [Bracketed entries are the work product of CIR staff]

**Table 1.** The Definitions and Functions of the Polysorbates in This Safety Assessment.<sup>4</sup>[Bracketed entries are the work product of CIR staff]




Table 1. The Definitions and Functions of the Polysorbates in This Safety Assessment. <sup>4</sup>
[Bracketed entries are the work product of CIR staff]





Table 1. The Definitions and Functions of the Polysorbates in This Safety Assessment. <sup>4</sup>
[Bracketed entries are the work product of CIR staff]



<b>Table 1.</b> The Definitions and Functions of the Polysorbates in This Safety Assessment. <sup>4</sup>
[Bracketed entries are the work product of CIR staff]






 Table 1. The Definitions and Functions of the Polysorbates in This Safety Assessment.<sup>4</sup>

 [Bracketed entries are the work product of CIR staff]



**Table 1.** The Definitions and Functions of the Polysorbates in This Safety Assessment.<sup>4</sup>[Bracketed entries are the work product of CIR staff]




Ingredient and CAS Definition No. Function Sorbeth-40 The hexaester of oleic acid and sorbeth-40. Surfactanthexaoleate emulsifying agent wherein u+v+w+x+y+z has an average value of 40. Sorbeth-50 The hexaester of oleic acid with a polyethylene glycol ether of sorbitol containing an average of 50 moles of Surfactanthexaoleate emulsifying ethylene oxide. agent CH<sub>2</sub> wherein u+v+w+x+y+z has an average value of 50. Sorbeth-2 The hexaester of a mixture of caprylic and capric acids with a polyethylene glycol ether of sorbitol Skincontaining an average of 2 moles of ethylene oxide. conditioning hexacaprylate/ caprate agent-emollient H<sub>2</sub>C CH<sub>2</sub>CI CH<sub>2</sub>CH<sub>2</sub>O (CH<sub>2</sub>CH<sub>2</sub>O) CH2 (CH<sub>2</sub>CH<sub>2</sub>O) wherein n is in each case 6 or 8, and u+v+w+x+y+z has an average value of 2.

 Table 1. The Definitions and Functions of the Polysorbates in This Safety Assessment.<sup>4</sup>

 [Bracketed entries are the work product of CIR staff]

Table 1. The Definitions and Functions of the Polysorbates in This Safety Assessment. <sup>4</sup>
[Bracketed entries are the work product of CIR staff]



# Table 2. Previous safety assessment of polysorbates and component moieties of the ingredients in this safety assessment.

Ingredients	Conclusion	Maximum concentration in report	Reference
Previous safety assessment of polyso	orbates		
<b>Polysorbates</b> – polysorbate 20, 21, 40, 60, 61, 65, 80, 81, 85	Safe as used.	>50%	1
Polysorbates – above plus PEG-20 sorbitan cocoate, PEG-40 sorbitan diisostearate, PEG-2 sorbitan isostearate, PEG-5 sorbitan isostearate, PEG-20 sorbitan isostearate, PEG-40 sorbitan lanolate, PEG-45 sorbitan lanolate, PEG-40 sorbitan laurate, PEG-40 sorbitan laurate, PEG-44 sorbitan laurate, PEG-45 sorbitan laurate, PEG-40 sorbitan laurate, PEG-40 sorbitan oleate, PEG-6 sorbitan oleate, PEG-80 sorbitan palmitate, PEG-40 sorbitan perisostearate, PEG-40 sorbitan peroleate, PEG-80 sorbitan stearate, PEG-40 sorbitan tetraoleate, PEG-60 sorbitan stearate, PEG-60 sorbitan tetraoleate, PEG-40 sorbitan tetraoleate, PEG-60 sorbitan tetraoleate, PEG-40 sorbitan tetraoleate, PEG-60 sorbitan tetraoleate, PEG-20 sorbitan tetrastearate, PEG-40 sorbitan tetraoleate, PEG-50 sorbitan tetrastearate, PEG-20 sorbitan tetraoleate, PEG-60 sorbitan triisostearate, PEG-40 sorbital sorbeth-40 hexaoleate), PEG-50 sorbitol hexaoleate(currently sorbeth-50 hexaoleate), PEG-30 sorbitol tetraoleate laurate (currently sorbeth-30 tetraoleate laurate), PEG-60 sorbitol tetrastearate	Safe as used.	10%	2
Sorbeth-6 beeswax, Sorbeth-8 beeswax, Sorbeth-20 beeswax	Safe for use as cosmetic ingredients under the present practices of use. The Expert Panel recommends that cosmetic formulations containing PEG-6, PEG-20, or PEG- 75 not be used on damaged skin.*	11%	6

**Table 2.** Previous safety assessment of polysorbates and component moieties of the ingredients in this safety assessment.

		Maximum concentration	
Ingredients	Conclusion	in report	Reference
Safety assessments of component	nts		
Beeswax, candelilla wax, carnauba wax, and Japan wax	Safe as used.	56%	9,15
Coconut oil, acid and related ingredients	Safe as used	100%	9,11,12,53
Isostearic acid	Safe as used.	26%	9,14
Lanolin acid	Safe as used	65%	9,13
Oleic acid, lauric acid, myristic acid, stearic acid	Safe in the present	> 50%; 43%	10,17
	practices of use and		
	concentration.		
Polyethylene glycols (PEG) - triethylene glycol and polyethylene (PEGs) -4, -6, -7, -8, -9,	Safe in the present	85%	7,18
-10, -12, -14, -16, -18, -20, -32, -33, -40, -45, -55, -60, -75, -80, -90, -100, -135, -150,	practices of use and		
-180, -200, -220, -240, -350, -400, -450, -500, -800, -2M, -5M, -7M, -9M, -14M, -20M,	concentration.		
-23M, -25M, -45M, -65M, -90M, -115M, -160M, and -180M and any PEG >= 4			
Sorbitan esters - sorbitan caprylate, sorbitan cocoate, sorbitan diisostearate, sorbitan	Safe as used.	9.1%	20-22
dioleate, sorbitan distearate, sorbitan isostearate, sorbitan laurate, sorbitan oleate, sorbitan			
olivate, sorbitan palmitate, sorbitan sesquiisosotearate, sorbitan stearate, sorbitan			
sesquioleate, sorbitan triisostearate, sorbitan trioleate, and sorbitan tristearate			
Stearates - butyl stearate, cetyl stearate, isobutyl stearate, isocetyl stearate, isopropyl	Safe as used.	87%	9,16
stearate, myristyl stearate, and octyl stearate			
Alkyl Esters	Safe as used	78%	19

\* In 2010, the Panel concluded that PEGs were safe as used and removed the caveat that PEGs should not be used on damaged skin.<sup>7</sup>

Property	Value	Reference
	sorbate 21	
Physical Form	Liquid/Oily liquid	23
Molecular Weight g/mol	390.5	23
Water Solubility	Dispersible	54
Other Solubility	•	
Ethanol	Soluble	54
Corn oil	Soluble	54
Sorbeth-6 laurate l	PEG-10 sorbitan laurate	
Physical Form	Liquid	54
Color	Clear yellow	54
Odor	Mild	54
Water Solubility g/L @ °C & pH	Soluble	54
Other Solubility		
Acetone	Soluble	54
Ethyl acetate	Soluble	54
Mineral oil	Insoluble	54
Polys	sorbate 20	
Physical Form	Liquid	23,55
Color	Lemon-amber	23,55
Odor	Characteristic	23,55
Molecular Weight g/mol	~1228	55
Molecular Volume m <sup>3</sup> /kmol		
Density/Specific Gravity @ 25°C	1.095	23,55
Water Solubility	Soluble	54,55
Other Solubility		
Ethanol	Soluble	54,55
Ethyl acetate	Soluble	54,55
Polys	sorbate 40	
Physical Form	Oily liquid or Vaseline-	56-59
5	like	
Odor	Characteristic	2,54
Density/Specific Gravity @ °C	1.05	59
Water Solubility	Soluble	54
Other Solubility		
Methanol	Soluble	54
Ethanol	Soluble	54
Mineral oil	Insoluble	54

**Table 3.** Chemical and physical properties of some polysorbates.

Property	Value	Reference
	Polysorbate 61	
Physical Form	Waxy solid	54,56,60
Color	Tan	54
Water Solubility	Dispersable	61
Other Solubility	*	
Ethylene glycol	Insoluble	61
Propylene glycol	Insoluble	61
]	Polysorbate 60	
Physical Form	Oily liquid	56
	Semigel	62
	Wax	63
Color	Lemon yellow	54
	Polysorbate 65	
		56,57
Physical Form	Waxy solid	54
Color	Tan	54
Odor	Faint, characteristic	54
Vater Solubility	Dispersible	54
Other Solubility		54
Ethanol	Soluble	
Methanol	Soluble	54 54
Vegetable and mineral oil	Soluble	54
]	Polysorbate 81	
hysical Form	Liquid	24
	May gel at room	57
	temperature	
Color	Clear	24
Ddor	Faint	54
Density/Specific Gravity @ 20°C	1.0356	24
@ 25 °C	1.032	24
@ 20°C	1032	24
@ 25 °C	1.0264	24
/iscosity kg/(s m) @ 20°C	0.672	24
riscosity kg/(s iii) @ 20 C	0.84	24
@ 25°C	0.84	24
Discuss different Samples	0.328	24
		24
/apor pressure mmHg@ °C	0.002	
Vapor Density mmHg	22.0	24
Melting Point °C	-33.9	24
	-32.7	
Boiling Point °C	0.100	24
Water Solubility g/L	~0.100	24
	~0.035	24
@ 20°C & pH 8.29-9.39	>0.500	24
Other Solubility		51
Ether	Dispersible	54 54
Ethylene glycol	Dispersible	54
Ethanol	Soluble	54
PEG	-20 sorbitan oleate	
Density/Specific Gravity @ °C	1.1/1.064	2
Other Solubility		
Dimethyl sulfoxide	Soluble	54
Ethanol	Soluble	54
Mineral oil	Soluble	54
Toluene	Soluble	54
1	Polysorbate 80	
Physical Form	Viscous, oily liquid	56,58,59,62-65
Color	Lemon to orange/amber	54,66
Ddor	Characteristic	54
Density/Specific Gravity @ °C	1.08	64
rensity/specific Oravity @ C	1.08	65,66
		59
lissosity balls m) @ °C	1.07-1.09	66
/iscosity kg/(s m)@ °C	0.3-0.5	54
Vater Solubility	Soluble	.+
PEG-	40 sorbitan lanolate	
Physical Form	Soft paste	61
Vater Solubility @ 65°C	Soluble	61
Other Solubility @ 65°C		
Dioxane	Soluble	61

Table 3. Chemical and physical properties of some polysorbates.

Property	Value	Reference
Sorbe	th-6 beeswax	
Physical Form	Waxy solid	67
Color	Tan	67
Odor	Fatty	67
Water Solubility	Insoluble	67
Other Solubility		
Corn oil	Soluble	67
Ethylene glycol	Insoluble	67
Mineral oil	Insoluble	67
Sorbet	h-20 beeswax	
Physical Form	Waxy solid	67
Color	Tan	67
Odor	Mild, fatty	67
Water Solubility g/L @ °C & pH	Insoluble	67
Other Solubility		67
Warm corn oil	Soluble	
Mineral oil	Dispersible	
Poly	vsorbate 85	
Physical Form	Liquid	56,58
	May gel at room	54,57
	temperature	
Color	Clear amber	54
Odor	Characteristic	54
Water Solubility	Dispersible	54
Other Solubility		54
Vegetable and mineral oils	Soluble	
PEG-40 s	orbitan peroleate	
Physical Form	Viscous, oily liquid	61
Color	Clear yellow	61
Odor	Faint characteristic	61
Water Solubility	Dispersible	61
Other Solubility	•	61
Mineral oil	Soluble	

**Table 3.** Chemical and physical properties of some polysorbates.

**Table 4.** Chemical and physical properties of generic Sorbitan monolaurate, ethoxylated ingredients.

Property	Value	Reference
Sorbitan monolaurate		
Physical Form	Liquid	23
Water Solubility g/L @ 20 °C & pH 6.3 and 7.9	<2.0	23
Sorbitan monostearate	e, ethoxylated	
Physical Form	Solid (wax)	25
Color	Colorless	25
Odor	Odorless	25
Density/Specific Gravity @ 23°C	1.007	25
@ 25°C	1.07	25
Vapor pressure mmHg @ 20°C	< 0. 0.75	25
@ 20°C	<0.1	25
Melting Point °C	45-50	25
C	39.6	25
Boiling Point °C	90.4	25
Water Solubility g/L @ 23°C	0.300	25
Other Solubility g/L		
Petroleum ether @ 23°C	1.800	25
Methanol @ 23°C	0.200	25
log K <sub>ow</sub> @ 23 °C & pH 6.4	0.03	25
Disassociation constants (pKa @ 23°C	0.199 x 10 <sup>-9</sup>	25

Table 5. The approximate ester content of some polysorbates.	!
<b>Table 5.</b> The approximate ester content of some polysorbates.	

Ingredient	Laurate (%)	Myristate (%)	Palmitate (%)	Stearate (%)	Oleate (%)	Other esters (%)
Polysorbate 20	39±2	26±1	12±1	12±2	ND	11±2
Polysorbate 21	40-60	14-25	6-15	0-7	0-11	0-24
Polysorbate 40	<1	2	87±2	10±1	ND	<1
Polysorbate 60	2±1	4±1	43±1	51±2	ND	<1
Polysorbate 80	<1	2	22±2	11±2	66±1	<1

ND=none detected

	# of Uses		exposure.	onc of Use (%) # of		ses	Max Conc o	f Use (%)	
	2015 1998**		2014	1981***	2015	1998	2014	1981	
		Polv	sorbate 20				sorbate 21		
Totals*	3013	770	0.00001-19.6	0.09->50	55	4	0.33-8	0.1-1	
Duration of Use	0010		0100001 1910	0.03 7 0 0			01000	011 1	
Leave-On	1639	446	0.00001-9.1	0.09->50	17	4	0.33-2	0.1-1	
Rinse-Off	1275	297	0.0006-19.6	0.09-25	38	NR NR	0.5-8	NR	
Diluted for (Bath) Use	99	27	0.0097-8.9	0.1-50	NR	NR	NR	NR	
Exposure Type		27	0.0097-0.9	0.1-50	IVIX	IVI	IVIX	IVIN	
1 11	226	20	0.00015.2.5	0.1.10	4	ND	0.5	ND	
Eye Area Incidental Ingestion	226 32	39 12	0.00015-3.5 0.01-5.8	0.1-10 0.09-5	4 NR	NR NR	0.5 NR	NR NR	
incidental ingestion	52		0.001-3.8 0.00001-3 <sup>d</sup> ;	0.09-3	INK	INK	INK	INK	
Insidental Inholation Spray	35; 546 <sup>a</sup> ;	22; 169 <sup>a</sup> ;	1		$6^{a}$	4 <sup>a</sup>	0.33 <sup>g</sup>	$0.1-1^{a}$	
Incidental Inhalation-Spray	397°	50 <sup>c</sup>	0.0019-3 <sup>a</sup> ; 0.76-2 <sup>c</sup>	<0.1->50 <sup>a</sup> ; 0.09-5 <sup>c</sup>	0	4	0.35	0.1-1	
			0.76-2	0.09-5					
Incidental Inhalation-Powder	52; 5 <sup>b</sup> ; 397 <sup>c</sup>	13. 50°	0.0006-9.1 <sup>b</sup> ;	0.1-1;	NR	NR	0.38 <sup>b</sup>	NR	
incluental initiatation-Powder	52; 5 ; 597	43; 50 <sup>c</sup>	0.0006-9.1°; 0.76-2°	0.09-5 <sup>c</sup>	INK	INK	0.58	INK	
Dermal Contact	2299	493	0.76-2	0.09-5	14	4	0.38-2	NR	
			0.0001-19.8 0.00018-4 <sup>e</sup> ;		14			INK	
Deodorant (underarm)	9 <sup>a</sup>	3ª	0.00018-4 ; 0.00082-3 <sup>f</sup>	0.1-5 <sup>a</sup>	NR	NR	NR	NR	
Hair - Non-Coloring	555	205	0.006-12.6	0.09-25	14	NR	0.33-8	NR	
Hair-Coloring	92	50	0.4-3.8	0.09-25	24	NR	2.4	NR	
Nail	11	6	0.000041-3.3	0.09-5	NR	NR	NR	NR	
Mucous Membrane	822	66	0.0006-19.6	0.09->50	3	NR	NR	NR	
Baby Products	32	3	0.00078-12.6	0.1-25	NR	NR	NR	NR	
Baby Hoddets	52	5	0.00070 12.0	0.1 25	III	THE	THK .	INK	
	2015	1998	2014	1981	2014	1998	2014	1981	
	2015		sorbate 40	1701	2014		sorbate 60	1701	
Totals*	80	32	0.008-5			332	0.0000001-6		
Duration of Use	80	32	0.008-3	0.09-10	1589	332	0.0000001-0	0.09-23	
9	15	24	0.000.5	0.00.10	1220	0.55	0.00000.4	0.00.05	
Leave-On	65	24	0.008-5	0.09-10	1228	255	0.00009-4	0.09-25	
Rinse-Off	15	8	1.5-3	0.09-5	358	77	0.0000001-6	0.09-5	
Diluted for (Bath) Use	NR	NR	NR	NR	3	NR	0.0015-0.06	0.1-10	
Exposure Type									
Eye Area	12	1	0.015-3.75	1-5	75	35	0.0021-3.8	0.09-10	
Incidental Ingestion	1	NR	NR	NR	13	NR	0.2-0.4	0.09-5	
				0.1-10 <sup>a</sup> ;	2; 635 <sup>a</sup> ;		0.0025-0.8 <sup>h</sup> ;		
Incidental Inhalation-Spray	24 <sup>a</sup> ; 21 <sup>c</sup>	13°; 3°	0.5-2.5ª	0.1-5°	2, 035 , 338°	93°; 59°	0.0005-4 <sup>a</sup> ;	$0.1 - 10^{a}$	
				0.1 5	550		2.4°		
					7; 10 <sup>b</sup> ;		0.053;		
Incidental Inhalation-Powder	21 <sup>c</sup>	3°	0.019-5 <sup>b</sup>	0.1-5 <sup>c</sup>	338°	59°	0.018-3.7 <sup>b</sup> ;	0.09-5	
							2.4°		
Dermal Contact	76	29	0.008-5	0.09-10	1302	297	0.00009-6	0.09-10	
Deodorant (underarm)	NR	NR	NR	NR	1 <sup>a</sup>	NR	0.02 <sup>f</sup>	NR	
Hair - Non-Coloring	1	2	0.8-2.5	0.09-5	156	22	0.0000001-5	0.1-25	
Hair-Coloring	NR	NR	NR	NR	107	1	0.002-2.5	1-5	
e	NR	1	NR	0.1-5	2	5	3.5	0.1-5	
Nail									
Nail Mucous Membrane	4 NR	NR NR	3 NR	NR NR	52 11	NR 3	0.0008-2 0.00009-1.5	0.09-10 NR	

**Table 6.** Current and historical frequency and concentration of use of polysorbates according to duration and exposure.<sup>1,2,6,8,15,31</sup>

			exposure.					
	# of U	Jses	Max Conc o		# of l	Uses	Max Conc of	<sup>c</sup> Use (%)
	2015	1998	2014	1981	2015	1998	2014	1981
		Polysorbate 61				Poly	sorbate 65	
Totals*	16	8	1-1.8	0.1-5	24	2	0.0003-3	1-5
Duration of Use		•		•				
Leave-On	16	8	1-1.8	0.1-5	21	NR	0.0003-3	NR
Rinse-Off	NR	NR	NR	0.1-5	3	2	0.002-0.15	1-5
Diluted for (Bath) Use	NR	NR	NR	NR	NR	NR	NR	NR
Exposure Type			1			1	1 1	
Eye Area	NR	NR	NR	NR	5	NR	0.5	NR
Incidental Ingestion	NR	NR	NR	NR	NR	NR	NR	NR
Incidental Inhalation-Spray	$9^{a}; 5^{c}$	4 <sup>c</sup>	NR	1-5 <sup>a</sup> ; 0.1-1 <sup>c</sup>	7 <sup>a</sup> ; 8 <sup>c</sup>	NR	NR	NR
Incidental Inhalation-Powder	1 <sup>b</sup> ; 5 <sup>c</sup>	3 <sup>b</sup> ; 4 <sup>c</sup>	1.8 <sup>b</sup>	$1-5^{\rm b}; 0.1-1^{\rm c}$	8°	NR	0.003-3 <sup>b</sup>	NR
Dermal Contact	16	8	1-1.8	0.1-5	24	1	0.0003-3	1-5
Deodorant (underarm)	NR	NR	NR	NR	NR	NR	0.0003 <sup>f</sup>	NR
Hair - Non-Coloring	NR	NR	NR	NR	NR	1	NR	NR
Hair-Coloring	NR	NR	NR	NR	NR	NR	NR	NR
Nail	NR	NR	NR	NR	NR	NR	0.002-0.003	NR
Mucous Membrane	NR	NR	NR	NR	NR	NR	NR	NR
Baby Products	1	4	NR	1-5	NR	NR	NR	NR
J. I.			i	· · ·		i	· · ·	
	2015	1998	2014	1981	2015	1998	2014	1981
	2010		sorbate 80	1701	2010		sorbate 81	1/01
Totals*	932	231	0.00031-18.1	0.01-25	NR	4	0.4-25.6	0.1-5
Duration of Use	754	231	0.00031-10.1	0.01-23			0.4-23.0	0.1-5
	750	122	0.00021.11.0	0.01.10	MD	1	0575	0.1.5
Leave-On	759	132	0.00031-11.9	0.01-10	NR	4	0.5-7.5	0.1-5
Rinse-Off	166	89	0.0038-18.1	0.09-10	NR	NR	0.4-25.6	0.1-5
Diluted for (Bath) Use	7	10	NR	0.1-25	NR	NR	5-7.5	NR
Exposure Type								
Eye Area	114	16	0.0024-11	0.09-5	NR	NR	0.5	NR
Incidental Ingestion	45	15	0.00031-1.5	0.09-1	NR	NR	NR	NR
Incidental Inhalation-Spray	15; 315 <sup>a</sup> ; 196 <sup>c</sup>	16; 71 <sup>a</sup> ; 13 <sup>c</sup>	$\begin{array}{c} 0.02\text{-}11.9^{i};\\ 0.0038\text{-}2^{a} \end{array}$	0.1-1; 0.09-10 <sup>a</sup> ; 0.09-10 <sup>c</sup>	NR	1 <sup>a</sup>	5	0.1-5 <sup>*</sup> 0.1-1
Incidental Inhalation-Powder	18;2 <sup>b</sup> ; 196 <sup>c</sup>	7; 13°	0.42-2; 0.005-2°	1-10; 0.09-10 <sup>b</sup> ; 0.09-10 <sup>c</sup>	NR	NR	5 <sup>b</sup>	0.1-1
Dermal Contact	731	122	0.00075-18.1	0.01-25	NR	3	0.5-25.6	0.1-1
Deodorant (underarm)	1 <sup>a</sup>	NR	NR	0.09-1 <sup>a</sup>	NR	NR	NR	NR
Hair - Non-Coloring	118	80	0.02-10	0.09-10	NR	1	0.4	0.1-5
Hair-Coloring	25	10	0.36	NR	NR	NR	NR	NR
Nail	7	2	NR	0.1-1	NR	NR	7.5	NR
Mucous Membrane	75	29	0.00031-1.5	0.09-25	NR	NR	5-7.5	NR
Baby Products	4	4	10	0.1-10	NR	NR	NR	NR
	2015	1998	2014	1981	2015	1998	2014	1998
			sorbate 85				rbitan isostearate	
Totals*	51	35	0.03-21.9	0.01->50	3	2	0.3	NR
Duration of Use	~1		1 0100-2117	0.01 200	0			111
paration of Ose			1					
Leave-On	23	28	0.03-6	0.01-10	3	2	0.3	NR

Leave-On	23	28	0.03-6	0.01-10	3	2	0.3	NR
Rinse-Off	15	7	5.5-21.9	0.09->50	NR	NR	NR	NR
Diluted for (Bath) Use	13	NR	0.03-0.055	NR	NR	NR	NR	NR
Exposure Type								
Eye Area	4	5	NR	0.09-5	NR	NR	NR	NR
Incidental Ingestion	NR	NR	NR	NR	NR	NR	NR	NR
Incidental Inhalation-Spray	1; 6 <sup>a</sup> ; 5 <sup>c</sup>	NR	NR	0.01-10 <sup>a</sup> ; 0.1-1 <sup>c</sup>	1 <sup>a</sup> ; 2 <sup>c</sup>	1 <sup>a</sup>	NR	NR
Incidental Inhalation-Powder	1; 5 <sup>c</sup>	NR	0.06-0.54 <sup>b</sup>	0.01-1 <sup>b</sup> ; 0.1-1 <sup>c</sup>	2°	NR	0.3 <sup>b</sup>	NR
Dermal Contact	51	30	0.03-21.9	0.01-10	3	NR	0.3	NR
Deodorant (underarm)	NR	NR	NR	NR	NR	NR	NR	NR
Hair - Non-Coloring	NR	4	NR	0.01-5	NR	NR	NR	NR
Hair-Coloring	NR	1	NR	>50	NR	NR	NR	NR
Nail	NR	NR	NR	NR	NR	1	NR	NR
Mucous Membrane	14	NR	0.03-0.55	NR	NR	NR	NR	NR
Baby Products	NR	NR	NR	NR	NR	NR	NR	NR

**Table 6.** Current and historical frequency and concentration of use of polysorbates according to duration and exposure.<sup>1,2,6,8,15,31</sup>

			exposure					
	# of	Uses	Max Conc	of Use (%)	# of L		Max Conc of	Use (%)
	2014	1998	2014	1998	2015	1998	2014	1998
		PEG-40 so	rbitan lanolate			PEG-10 s	orbitan laurate	
Totals*	NR	7	NR	NR	2	2	NR	NR
Duration of Use								
Leave-On	NR	4	NR	NR	1	NR	NR	NR
Rinse-Off	NR	3	NR	NR	1	2	NR	NR
Diluted for (Bath) Use	NR	NR	NR	NR	NR	NR	NR	NR
Exposure Type								.,
	NR	NR	NR	NR	NR	NR	NR	NR
Eye Area Incidental Ingestion	NR	NR	NR	NR	NR	NR	NR	NR
Incidental Inhalation-Spray	NR	1 <sup>a</sup>	NR	NR	1 <sup>a</sup>	NR	NR	NR
Incidental Inhalation-Powder	NR	NR	NR	NR	NR	NR	NR	NR
Dermal Contact	NR	NR	NR	NR	2	NR	NR	NR
Deodorant (underarm)	NR	NR	NR	NR	NR	NR	NR	NR
Hair - Non-Coloring	NR	5	NR	NR	NR	1	NR	NR
Hair-Coloring	NR	2	NR	NR	NR	NR	NR	NR
Nail	NR	NR	NR	NR	NR	1	NR	NR
Mucous Membrane	NR	NR	NR	NR	NR	NR	NR	NR
Baby Products	NR	NR	NR	NR	NR	NR	NR	NR
Baby Houdets	INK		INK	INK	INK	INK	INK	INK
	2015	1998	2014	1998	2015	1998	2014	1998
		PEG-44 so	rbitan laurate	•		PEG-80 s	orbitan laurate	
Fotals*					93	34	0.0002-4.2	NR
Duration of Use	Ū.	0	010 2					1111
Leave-On	1	6	2	NR	20	6	0.0002-0.059	NR
	2	2	0.5	1		28	1 1	
Rinse-Off		-		NR	60 13		2-4.2	NR
Diluted for (Bath) Use	NR	NR	NR	NR	15	NR	2.5	NR
Exposure Type							· · · · ·	
Eye Area	NR	NR	NR	NR	NR	NR	NR	NR
Incidental Ingestion	NR	NR	NR	NR	1	NR	0.059	NR
Incidental Inhalation-Spray	1 <sup>a</sup>	1 <sup>a</sup>	NR	NR	NR	NR	NR	NR
Incidental Inhalation-Powder	NR	NR	NR	NR	NR	NR	0.0002-0.0098 <sup>b</sup>	NR
Dermal Contact	3	8	2	NR	70	14	0.0002-4.2	NR
Deodorant (underarm)	NR	NR	NR	NR	NR	NR	NR	NR
Hair - Non-Coloring	NR	NR	0.5	NR	22	20	4.2	NR
Hair-Coloring	NR	NR	NR	NR	NR	NR	NR	NR
Nail	NR	NR	NR	NR	NR	NR	NR	NR
Mucous Membrane	NR	NR	NR	NR	36	2	0.059-4.2	NR
Baby Products	NR	NR	NR	NR	33	15	4.2	NR
	2015	1000	2014	1000	2015	1000	2014	1000
	2015	1998 BEC 2	2014 orbitan oleate	1998	2015	1998	2014 Prbitan peroleate	1998
Fotals*	1	4	NR	ND	53		0.16-4	ND
	1	4	INK	NR	53	13	0.10-4	NR
Duration of Use				1.110				
Leave-On	1	4	NR	NR	51	8	0.16-4	NR
Rinse-Off	NR	NR	NR	NR	2	NR	NR	NR
Diluted for (Bath) Use	NR	NR	NR	NR	NR	5	NR	NR
Exposure Type								
Eye Area	NR	NR	NR	NR	8	NR	NR	NR
Incidental Ingestion	NR	NR	NR	NR	NR	NR	NR	NR
	$1^{a}$	1 <sup>a</sup>	NR	NR	14 <sup>a</sup> ; 13 <sup>c</sup>	6 <sup>a</sup> ; 1 <sup>c</sup>	4 <sup>a</sup>	NR
		NR	NR	NR	13°	1; 1 <sup>c</sup>	0.3-0.9 <sup>b</sup>	NR
Incidental Inhalation-Powder	NR		NTD	NR	50	13	0.16-1	NR
Incidental Inhalation-Powder Dermal Contact	1	3	NR					ND
ncidental Inhalation-Powder Dermal Contact Deodorant (underarm)	1 NR	NR	NR	NR	NR	NR	NR	NR
Incidental Inhalation-Powder Dermal Contact Deodorant (underarm) Hair - Non-Coloring	1 NR NR	NR 1	NR NR	NR NR	3	NR	4	NR
ncidental Inhalation-Powder Dermal Contact Deodorant (underarm) Hair - Non-Coloring Hair-Coloring	1 NR NR NR	NR 1 NR	NR NR NR	NR NR NR	3 NR	NR NR	4 NR	NR NR
Incidental Inhalation-Powder Dermal Contact Deodorant (underarm) Hair - Non-Coloring Hair-Coloring Nail	1 NR NR NR NR	NR 1 NR NR	NR NR NR NR	NR NR NR NR	3 NR NR	NR NR NR	4 NR NR	NR NR NR
Incidental Inhalation-Spray Incidental Inhalation-Powder Dermal Contact Deodorant (underarm) Hair - Non-Coloring Hair-Coloring Nail Mucous Membrane Baby Products	1 NR NR NR	NR 1 NR	NR NR NR	NR NR NR	3 NR	NR NR	4 NR	NR NR

 Table 6. Current and historical frequency and concentration of use of polysorbates according to duration and exposure.<sup>1,2,6,8,15,31</sup>

	# of 1	Uses	Max Conc o	of Use (%)	# of Uses Max Conc			of Use (%)
1	2015	1998	2014	1998	2015	1998	2014	1998
			rbitan stearate	PEG-40 sorbitan tetraoleate				
Fotals* 1 1		1	NR NR		1 1		NR N	
Duration of Use				•				
Leave-On	1	NR	NR	NR	1	1	NR	NR
Rinse-Off	NR	1	NR	NR	NR	NR	NR	NR
Diluted for (Bath) Use	NR	NR	NR	NR	NR	NR	NR	NR
Exposure Type								
Eye Area	NR	NR	NR	NR	NR	NR	NR	NR
Incidental Ingestion	NR	NR	NR	NR	NR	NR	NR	NR
Incidental Inhalation-Spray	NR	NR	NR	NR	1 <sup>c</sup>	1°	NR	NR
Incidental Inhalation-Powder	1 <sup>a</sup>	NR	NR	NR	1°	1°	NR	NR
Dermal Contact	1	1	NR	NR	1	1	NR	NR
Deodorant (underarm)	NR	NR	NR	NR	NR	NR	NR	NR
Hair - Non-Coloring	NR	NR	NR	NR	NR	NR	NR	NR
Hair-Coloring	NR	NR	NR	NR	NR	NR	NR	NR
Nail	NR	NR	NR	NR	NR	NR	NR	NR
Mucous Membrane	NR	NR	NR	NR	NR	NR	NR	NR
Baby Products	1	NR	NR	NR	NR	NR	NR	NR
	2015	1998	2014	1999				
	2015		2014 1-20 beeswax	1999				
Totals*	2015 9			1999 0.5-2.8				
Totals* Duration of Use		Sorbeth	-20 beeswax	1				
		Sorbeth	-20 beeswax	1				
Duration of Use	9	Sorbeth 16	-20 beeswax 0.5-2.8	0.5-2.8				
Duration of Use Leave-On	<b>9</b> 9	<b>Sorbeth</b> 16	0.5-2.8	0.5-2.8				
Duration of Use Leave-On Rinse-Off Diluted for (Bath) Use	<b>9</b> 9 NR	Sorbeth 16 1 NR	0.5-2.8	0.5-2.8				
Duration of Use Leave-On Rinse-Off	<b>9</b> 9 NR	Sorbeth 16 1 NR	0.5-2.8	0.5-2.8				
Duration of UseLeave-OnRinse-OffDiluted for (Bath) UseExposure TypeEye Area	9 9 NR NR	Sorbeth 16 <i>I</i> <i>NR</i> <i>NR</i>	-20 beeswax 0.5-2.8 0.5-2.8 NR NR	0.5-2.8 NR NR NR NR				
Duration of Use Leave-On Rinse-Off Diluted for (Bath) Use Exposure Type	9 9 NR NR 7	Sorbeth 16 <i>I</i> <i>NR</i> <i>NR</i> <i>NR</i> 11	-20 beeswax 0.5-2.8 0.5-2.8 NR NR 2.8	0.5-2.8 NR NR NR 2.8				
Duration of Use         Leave-On         Rinse-Off         Diluted for (Bath) Use         Exposure Type         Eye Area         Incidental Ingestion         Incidental Inhalation-Spray	9 9 NR NR 7 1	Sorbeth           16           1           NR           NR           11           4	-20 beeswax 0.5-2.8 0.5-2.8 NR NR 2.8 2.5	0.5-2.8 NR NR NR 2.8 2.5				
Duration of Use         Leave-On         Rinse-Off         Diluted for (Bath) Use         Exposure Type         Eye Area         Incidental Ingestion         Incidental Inhalation-Spray         Incidental Inhalation-Powder	9 9 NR NR 7 1 NR NR 1	Sorbeth           16           NR           NR           11           4           NR	-20 beeswax 0.5-2.8 0.5-2.8 NR NR 2.8 2.5 NR	0.5-2.8 NR NR NR 2.8 2.5 NR				
Duration of Use         Leave-On         Rinse-Off         Diluted for (Bath) Use         Exposure Type         Eye Area         Incidental Ingestion         Incidental Inhalation-Spray         Incidental Inhalation-Powder         Dermal Contact	9 9 NR NR 7 1 NR NR 1 NR 1 NR	Sorbeth           16           NR           NR           11           4           NR           NR	-20 beeswax 0.5-2.8 0.5-2.8 0.5-2.8 NR 0.5-2.8 0.5-2.8 0.5-1 NR 0.5-1 NR	0.5-2.8 NR NR 2.8 2.5 NR NR				
Duration of Use         Leave-On         Rinse-Off         Diluted for (Bath) Use         Exposure Type         Eye Area         Incidental Ingestion	9 9 NR NR 7 1 NR NR 1	Sorbeth           16           1           NR           11           4           NR           NR           4	-20 beeswax 0.5-2.8 0.5-2.8 0.5-2.8 NR 0.5-2.8 0.5-10	0.5-2.8 NR NR 2.8 2.5 NR NR 0.5-1				
Duration of Use         Leave-On         Rinse-Off         Diluted for (Bath) Use         Exposure Type         Eye Area         Incidental Ingestion         Incidental Inhalation-Spray         Incidental Inhalation-Powder         Dermal Contact         Deodorant (underarm)         Hair - Non-Coloring         Hair-Coloring	9 9 NR NR 7 1 NR NR 1 NR 1 NR	Sorbeth 16 1 NR NR 11 4 NR NR 4 NR 4 NR	-20 beeswax 0.5-2.8 0.5-2.8 0.5-2.8 NR 0.5-2.8 0.5-2.8 0.5-1 NR 0.5-1 NR	0.5-2.8 NR NR 2.8 2.5 NR NR 0.5-1 NR				
Duration of Use         Leave-On         Rinse-Off         Diluted for (Bath) Use         Exposure Type         Eye Area         Incidental Ingestion         Incidental Inhalation-Spray         Incidental Inhalation-Powder         Dermal Contact         Deodorant (underarm)         Hair - Non-Coloring	9 9 NR NR 7 1 NR NR 1 NR NR 1 NR	Sorbeth           16           1           NR           11           4           NR           4           NR           NR           NR           NR           NR           NR	-20 beeswax 0.5-2.8 0.5-2.8 0.5-2.8 NR 0.5-2.8 0.5-1 0.5-1 NR NR NR	0.5-2.8 NR NR 2.8 2.5 NR NR 0.5-1 NR NR NR				
Duration of Use         Leave-On         Rinse-Off         Diluted for (Bath) Use         Exposure Type         Eye Area         Incidental Ingestion         Incidental Inhalation-Spray         Incidental Inhalation-Powder         Dermal Contact         Deodorant (underarm)         Hair - Non-Coloring         Hair-Coloring	9 9 NR NR 7 1 NR NR 1 NR NR NR NR NR NR	Sorbeth 16 1 NR NR 11 4 NR NR 4 NR NR NR NR NR	-20 beeswax 0.5-2.8 0.5-2.8 0.5-2.8 NR 0.5-2.8 0.5-1 0.5-1 NR NR NR NR NR	0.5-2.8 NR NR 2.8 2.5 NR NR 0.5-1 NR NR NR NR NR				

NR - no reported use

\* Because each ingredient may be used in cosmetics with multiple exposure types, the sum of all exposure types may not equal the sum of total uses. \*\* The year that the Council survey was conducted in the previous report. In the report published in 2000, the only concentration of use data that were provided was the following: "...PEG-60 sorbitan tetratoleate, PEG-40 sorbitan tetraoleate, and PEG-160 sorbitan Triisostearate are used in cosmetics at concentrations of 0.5% to 10%..." in 1998. Since the data from the 2000 report is limited, the concentration of use data from the 1984 report are provided here to give a better historical perspective.

\*\*\* At the time of the 1984 safety assessment, concentration of use data were not reported by the FDA; 1981 data were presented. These data were presented in ranges so the limits of the ranges are represented here.

<sup>a</sup> It is possible these products are sprays, but it is not specified whether the reported uses are sprays.

<sup>b</sup> It is possible these products are powders, but it is not specified whether the reported uses are powders.

<sup>c</sup> Not specified whether a spray or a powder, but it is possible the use can be as a spray or a powder, therefore the information is captured in both categories.

<sup>d</sup> Aerosol hair spray 0.027%-3%; pump hair spray 0.4%-1%; spray body and hand products 0.00001%-1.2%; spray moisturizing products 0.1%. <sup>e</sup> Spray deodorants.

f Not spray deodorants.

<sup>g</sup> Aerosol hair spray.

<sup>h</sup> Spray body and hand products 0.083%-0.8%.

<sup>i</sup> Aerosol hair spray 0.078%-1.6%; pump hair spray 0.02%-0.2%; spray face and neck products 0.39%.

			in this	safety assessme	nt. <sup>5,31</sup>			
		Maximum		Maximum		Maximum		Maximum
		Concentration		Concentration		Concentration		Concentration
Use type	Uses	(%)	Uses	(%)	Uses	(%)	Uses	(%)
	PEG-30 s	orbitan beeswax	PEG-20	sorbitan cocoate		-40 sorbitan isostearate	PEG-20	sorbitan laurate
Total/range	1	NR	14	0.03-0.3	2	1	1 1	NS
Duration of use	-			0100 010		-	-	115
Leave-on	1	NR	12	0.03-0.3	2	1	NS	NS
Rinse-off	NR	NR	2	0.06	NR	NR	1	NS
Diluted for (bath)	ND	ND	ND	ND	ND	ND	NC	NG
use	NR	NR	NR	NR	NR	NR	NS	NS
Exposure type*								
Eye area	1	NR	1	NR	NR	NR	NS	NS
Incidental	NR	NR	NR	NR	NR	NR	NS	NS
ingestion	141	1VIX	INK	INK	INK	MK	145	115
Incidental	NR	NR	6 <sup>a</sup> ; 3 <sup>c</sup>	NR	2 <sup>a</sup>	$1^{a}$	NS	NS
Inhalation-sprays		m	0,5	T III	-	1	115	115
Incidental	NR	NR	3°	0.03-0.3 <sup>b</sup>	NR	NR	NS	NS
inhalation-powders			-					
Dermal contact	1	NR	14	0.03-0.3	2	NR	1	NS
Deodorant	NR	NR	NR	NR	NR	NR	NS	NS
(underarm) Hair-noncoloring	NR	NR	NR	NR	NR	1	NS	NS
Hair-coloring	NR	NR	NR	NR	NR	I NR	NS	NS
Nail	NR	NR	NR	NR	NR	NR	NS	NS
Mucous								
Membrane	NR	NR	NR	NR	NR	NR	NS	NS
Baby	NR	NR	NR	NR	NR	NR	NS	NS
,	L.							
	<b>PEG-40</b>	sorbitan laurate	PEG-75	sorbitan laurate	PEG-6	sorbitan oleate	PEG-3 s	orbitan stearate
Total/range	NR	0.25-2	NR	0.5-2	NR	0.43	3	NR
Duration of use								
Leave-on	NR	2	NR	NR	NR	0.43	2	NR
Rinse-off	NR	0.25-0.5	NR	0.5-2	NR	NR	1	NR
Diluted for (bath)	NR	NR	NR	NR	NR	NR	NR	NR
use	TUR	TUK	THE	TUK	111	INK	THE	INK
Exposure type								
Eye area	NR	NR	NR	NR	NR	NR	NR	NR
Incidental	NR	NR	NR	NR	NR	NR	NR	NR
ingestion								
Incidental	NR	NR	NR	NR	NR	NR	NR	NR
Inhalation-sprays Incidental								
inhalation-powders	NR	NR	NR	NR	NR	NR	NR	NR
Dermal contact	NR	2	NR	2	NR	0.43	3	NR
Deodorant								
(underarm)	NR	NR	NR	NR	NR	NR	NR	NR
Hair-noncoloring	NR	0.5	NR	0.5	NR	NR	NR	NR
Hair-coloring	NR	0.25	NR	NR	NR	NR	NR	NR
Nail	NR	NR	NR	NR	NR	NR	NR	NR
Mucous	NR	NR	NR	NR	NR	NR	NR	NR
Membrane								
Baby	NR	NR	NR	NR	NR	NR	NR	NR

**Table 7.** Frequency of use according to duration and exposure of polysorbates that are reviewed for the first time in this safety assessment.<sup>5,31</sup>

		M	in this sa	fety assessmen	nt. <sup>5,31</sup>	Martin		M	
		Maximum Concentration		Maximum Concentration		Maximum Concentration		Maximum Concentration	
Use type	Uses	(%)	Uses	(%)	Uses	(%)	Uses	(%)	
Ose type	Uses	(70)		0 sorbitan		0 sorbitan		60 sorbitan	
	PEG-6 sor	bitan stearate		earate		aoleate	tetraoleate		
Total/range	2	3.4	1	NS	1	10	NR	0.5-0.9	
Duration of use						-			
Leave-on	NR	NR	1	NS	NR	NR	NR	0.5-0.9	
Rinse-off	2	3.4	NR	NS	1	10	NR	NR	
Diluted for (bath)	NR	NR	NR	NS	NR	NR	NR	NR	
use	INK	INK	INK	ND	INK	INK	INK	INK	
Exposure type									
Eye area	NR	NR	NR	NS	NR	NR	NR	NR	
Incidental	NR	NR	NR	NS	NR	NR	NR	NR	
ingestion									
Incidental Inhalation-sprays	NR	NR	NR	NS	NR	NR	NR	$0.5-0.8^{a}$	
Incidental									
inhalation-powders	NR	NR	NR	NS	NR	NR	NR	0.9 <sup>c</sup>	
Dermal contact	2	3.4	1	NS	1	10	NR	0.8-0.9	
Deodorant (underarm)	NR	NR	NR	NS	NR	NR	NR	NR	
Hair-noncoloring	NR	NR	NR	NS	NR	NR	NR	0.5	
Hair-coloring	NR	NR	NR	NS	NR	NR	NR	NR	
Nail	NR	NR	NR	NS	NR	NR	NR	NR	
Mucous	NR	NR	NR	NS	NR	NR	NR	NR	
Membrane									
Baby	NR	NR	NR	NS	NR	NR	NR	NR	
	DEC 1	(0			C	1.41.20			
		60 sorbitan ostearate	Sorboth	n-6 beeswax		beth-30 sostearate	Sorbeth.	4 tetraoleate	
Total/range	4	NR	7	2	1	NR	4	NR	
Duration of use	-	MK	1	2	1				
Leave-on	NR	NR	7	2	1	NR	4	NR	
Rinse-off	4	NR	NR	NR	NR	NR	NR	NR	
Diluted for (bath)	ND								
use	NR	NR	NR	NR	NR	NR	NR	NR	
Exposure type									
Eye area	NR	NR	3	NR	NR	NR	NR	NR	
Incidental	NR	NR	NR	NR	NR	NR	NR	NR	
ingestion	THE THE	THX .	T IX	T III	INK	THX .	INK	THE .	
Incidental Inhalation-sprays	NR	NR	NR	NR	$1^{c}$	NR	NR	NR	
Incidental	NR	NR	NR	NR	1 <sup>c</sup>	NR	NR	NR	
inhalation-powders Dermal contact	1	NR	7	2	1	NR	4	NR	
Deodorant	-								
(underarm)	NR	NR	NR	NR	NR	NR	NR	NR	
Hair-noncoloring	3	NR	NR	NR	NR	NR	NR	NR	
Hair-coloring	NR	NR	NR	NR	NR	NR	NR	NR	
Nail	NR	NR	NR	NR	NR	NR	NR	NR	
Mucous Membrane	1	NR	NR	NR	NR	NR	NR	NR	
Baby	NR	NR	NR	NR	NR	NR	NR	NR	
Duby	1111	111	1111	1111	111	1111	1111	111	

**Table 7.** Frequency of use according to duration and exposure of polysorbates that are reviewed for the first time in this safety assessment.<sup>5,31</sup>

		Maximum Concentration		Maximum Concentration		Maximum Concentration		Maximum Concentration
Use type	Uses	(%)	Uses	(%)	Uses	(%)	Uses	(%)
		-6 tetraoleate		30 tetraoleate		40 tetraoleate		0 tetraoleate
Total/range	NR	0.21	10	0.11-10.8	2	0.5	1	NR
Duration of use								
Leave-on	NR	0.21	4	NR	1	0.5	1	NR
Rinse-off	NR	NR	6	0.11-10.8	1	NR	NR	NR
Diluted for (bath) use	NR	NR	NR	NR	NR	NR	NR	NR
Exposure type								
Eye area	NR	NR	NR	NR	NR	NR	NR	NR
Incidental ingestion	NR	NR	NR	NR	NR	NR	NR	NR
Incidental Inhalation-sprays	NR	NR	NR	NR	1 <sup>b</sup>	NR	1 <sup>a</sup>	NR
Incidental inhalation- powders	NR	0.21	NR	NR	1 <sup>b</sup>	0.5°	NR	NR
Dermal contact	NR	0.21	10	0.11-10.8	2	0.5	1	NR
Deodorant (underarm)	NR	NR	NR	NR	NR	NR	NR	NR
Hair-noncoloring	NR	NR	NR	NR	NR	NR	NR	NR
Hair-coloring	NR	NR	NR	NR	NR	NR	NR	NR
Nail	NR	NR	NR	NR	NR	NR	NR	NR
Mucous Membrane	NR	NR	NR	NR	NR	NR	NR	NR
Baby	NR	NR	NR	NR	NR	NR	NR	NR

**Table 7.** Frequency of use according to duration and exposure of polysorbates that are reviewed for the first time in this safety assessment.<sup>5,31</sup>

NR = Not Reported; NS = Not Surveyed; Totals = Rinse-off + Leave-on Product Uses.

Note: Because each ingredient may be used in cosmetics with multiple exposure types, the sum of all exposure type uses may not equal the sum total uses.

\*Because each ingredient may be used in cosmetics with multiple exposure types, the sum of all exposure types may not equal the sum of total uses.

<sup>a</sup> It is possible these products <u>may</u> be sprays, but it is not specified whether the reported uses are sprays.

<sup>b</sup> Not specified whether a powder or a spray, so this information is captured for both categories of incidental inhalation.

<sup>c</sup> It is possible these products <u>may</u> be powders, but it is not specified whether the reported uses are powders.

<b>Table 8.</b> Ingredients for which there were no reported current or historic uses from the VCRP or the Council. <sup>6,1</sup>
--

0 21

PEG-2 sorbitan isostearate	Sorbeth-2 hexaoleate
PEG-5 sorbitan isostearate	Sorbeth-40 hexaoleate
PEG-75 sorbitan lanolate	Sorbeth-50 hexaoleate
PEG-20 sorbitan oleate	Sorbeth-6 hexastearate
PEG-40 sorbitan oleate	Sorbeth-150 hexastearate
PEG-80 sorbitan palmitate	Sorbeth-3 isostearate
PEG-40 sorbitan perisostearate	Sorbeth-6 laurate
PEG-4 sorbitan stearate*	Sorbeth-2/oleate/dimer dilinoleate crosspolymer
PEG-60 sorbitan stearate	Sorbeth-20 pentaisostearate
PEG-60 sorbitan tetrastearate	Sorbeth-30 pentaisostearate
PEG-4 sorbitan triisostearate	Sorbeth-40 pentaisostearate
PEG-20 sorbitan triisostearate	Sorbeth-50 pentaisostearate
PEG-2 sorbitan trioleate	Sorbeth-40 pentaoleate
PEG-3 sorbitan tristearate	Sorbeth-20 tetraisostearate
Sorbeth-2 beeswax	Sorbeth-40 tetraisostearate
Sorbeth-8 beeswax	Sorbeth-50 tetraisostearate
Sorbeth-2 cocoate	Sorbeth-30 tetraoleate laurate
Sorbeth-2 hexacaprylate/caprate	Sorbeth-60 tetrastearate
Sorbeth-12 hexacocoate	Sorbeth-3 tristearate
Sorbeth-2 hexaisostearate	Sorbeth-160 tristearate
Sorbeth-2 hexalaurate	Sorbeth-450 tristearate

\* The Council has not completed the survey for concentration of use data.

Table 9.	Regulations cor	trolling the use	of polysorbates.
Lable 21	regulations con	moning the use	or porysoroutes.

Ingredient	Regulation	Citation
Polysorbate 20, 60, 65, and 80	Approved as diluents in color additives for drug use.	21CFR73.1;
		21CFR73.1001
Polysorbates 20, 60, and 80	Approved for direct use in all food types as synthetic flavorings.	21CFR172.623
Polysorbate 80	Approved to be used with carrageenan to make chewing gum bases and related substances.	21CFR172.623
Polysorbate 60, 65, and 80	Approved as multipurpose additives.	21CFR172.836;
		21CFR172.838;
		21CFR172.840]
Polysorbate 20	Permitted as a secondary direct food additive for human consumption.	21CFR173.310
Polysorbate 60, 65, and 80	Approved as defoaming agents in food for human consumption.	21CFR173.340
Polysorbate 20, 40, 60, and 80; PEG-3 sorbitan stearate; and PEG-3 sorbitan oleate	Approved for indirect addition to all food types as components of adhesives.	21 CFR 175.105
PEG-40 sorbitan laurate, PEG-6 sorbitan stearate, PEG-40 sorbitan stearate, PEG-6 sorbitan oleate, PEG-40 sorbitan tetraoleate, and PEG-40 sorbitan peroleate	May be used as indirect food additives as a defoaming agent in the manufacture of paper and paperboard.	12CFR176.210
Polysorbate 20, 40, 60, 65, 80, and 85, and PEG-3 sorbitan oleate	Approved for indirect addition to all food types as emulsifiers and/or surfactants.	21 CFR 178.3400
PEG-3 sorbitan oleate	May be used as a component of paper and paperboard in contact with dry food.	21CFR180
Polysorbate 80	Approved as an ophthalmic demulcent.	21CFR349.12
Polysorbate 60 and 80	Approved for use in animal feed and drinking water.	21CFR573.840;
-	•	21CFR573.860
Polysorbate 80	May be used to denature spirits.	27CFR21.68;
	-	27CFR21.151

 Table 10.
 Penetration enhancement studies of some polysorbates. <sup>38</sup>

Ingredient	Chemical/drug tested	Results; notes
Polysorbate 20 (5%)	Albuterol sulfate	ER compared to control (saline buffer)=3.43±0.52; ER compared to vehicle (ethanol)=1.26±0.32. Thawed, hairless rat skin pretreated with test substance using Franz cells.
Polysorbate 65 (5%)	Albuterol sulfate	ER compared to control (saline buffer)=4.74±0.23; ER compared to vehicle (ethanol)=1.75±0.29. Thawed, hairless rat skin pretreated with test substance using Franz cells.
Polysorbate 80 (5%)	Albuterol sulfate	ER compared to control (saline buffer)=2.95±0.45; ER compared to vehicle (ethanol)=1.09±0.17. Thawed, hairless rat skin pretreated with test substance using Franz cells.

ER=Enhancement ratio

Animal	Route	Duration	Dose	Comments
		Polysor	bate 20	
Rat	Oral	1 month	250 mg/kg	Well tolerated
	Oral	90 days	500 mg/kg	Diarrhea
Mouse	Oral	1 month	10 mg/kg	Well tolerated
		Polysor	bate 80	
Dog	Oral	90 days	5 mL/kg	As 1% of formulation;
-		-	-	well tolerated
Rat	Oral	Not reported	350 mg/kg	Well tolerated
	Oral	4 weeks	5 mL/kg	1%; well tolerated
	Oral	7 days	10 mL/kg	1%; well tolerated
	Intravenous	Not reported	100 mg/kg	Well tolerated
Mouse	Intraperitoneal	1 month	10 mL/kg	2%; well tolerated
	Intranasal	3 days	10 µL/nostril	0.2%; well tolerated
Primate	Oral	Efficacy	5 mL/kg	1%; well tolerated

**Table 11.** Highest reported NOAELs for polysorbate 20 and polysorbate 80reported in a survey of 4 research organizations.<sup>39</sup>

Table 12. In vivo human irritation studies of some pol	ysorbates.
--	------------

Ingredient (concentration)	Assay	Results; notes	Reference
Polysorbate 60 (concentration not specified in a cream or	Administered to the foreheads. Amount and n not specified.	Urticaria observed at application sites at 20 min caused by both polysorbate 60-based cream and polysorbate 60. There	25
100%)	Ĩ	was no effect of either the polysorbate 60 or the cream on the dorsal and arm skin	
Polysorbate 60 (1% in DMEM)	Human patch test scored according to ICDRG. Patches were in place for 2 days in Haye's chambers. n=30.	Irritation score=0.4 out of 4.	45
Polysorbate 80 (100%)	Test substance administered for increasing time periods: 15 min-4 h and observed at 24, 48, and 72 h. n=29	1 positive reaction. Control of 20% sodium dodecyl sulfate exhibited 24 of 29 reactions.	44
Polysorbate 80 (100%)	Test substance administered for increasing time periods: 15 min-4 h and observed at 24, 48, and 72 h. n=24	1 positive reaction. Control of 20% sodium dodecyl sulfate exhibited 8 of 27 reactions.	46
Sorbitan monostearate, ethoxylated (25% aqueous)	10 drops of the solution administered to the scalp twice/d for 16 weeks. n=68	Irritation score 1 out of 68. Mild redness observed in 1 subject. Not irritating.	25

## Table 13. Ocular irritation assays of some polysorbates.

Ingredient (concentration)	Assay	Results; notes	Reference
	Non	-human	
Polysorbate 20 (10%)	Draize test	Maximal average score=0.7; 24-h average score=0.0	48
Polysorbate 20 (2%)	Draize test	Not an ocular irritant	47
Polysorbate 20 (10%)	Draize test	Maximum average total score=0.7; 24-h score=0. Not an ocular irritant.	49
Polysorbate 81 (10% in light nineral oil)	Draize test using New Zealand White Rabbits (n=9)	Irritation score=0 out of 4; not irritating. Eyes were washed 2 sec after administration in 3 rabbits. Eyes were observed at 1, 24, 48, 72 h and 7 days.	24
Polysorbate 81 (100%)	Draize test using New Zealand White Rabbits (n=9)	Irritation score=0 out of 4; not irritating. Eyes were washed 2 sec after administration in 3 rabbits. Eyes were observed at 1, 24, 48, 72 h and 7 days.	24
Sorbitan monostearate, ethoxylated 0.1 g in water)	Draize test using New Zealand White Rabbits (n=3)	Irritation score-0 out of 110; not irritating. Did not produce any eye irritation or any eye discharge throughout the 72-h observation period. No lesions such as pannus, staining were observed.	25
Sorbitan monolaurate, ethoxylated 100%; 0.1 mL)	Draize test using New Zealand White rabbits (n=9)	Irritation score=0 out of 4; not irritating. Eyes were washed 2 sec after administration in 3 rabbits.	23
	In	vitro	
Polysorbate 20 (not provided)	EpiOcular test over 7 laboratories	Not predicted to be an ocular irritant. Average mean cell viability 97.40±6.49% of distilled water control.	51
Polysorbate 20 (2%)	Red blood cell hemolysis assay	Predicted to be a minimal ocular irritant.	47
Polysorbate 20 (2%)	K562 cell assay	Predicted to be a minimal ocular irritant.	47
Polysorbate 20 (5% in saline; 200	STE using SIRC cells (CCL-60). Exposure for 5 min.	Predicted to be an irritant.	50
Polysorbate 20 (100%; 50 µL)	EpiOcular assay	Predicted to be a non-irritant.	50
Polysorbate 20 (100%; 200 µL)	HET-CAM assay (Fertilized chicken eggs (white leghorn species) with microscopic evaluation of hemorrhage, lysis, and coagulation at 0.5, 2, and 5 min.	Predicted to be an irritant.	50
Polysorbate 20 (100%)	HET-CAM assay (Same as above but evaluation of time to hemorrhage, lysis, and coagulation)	Predicted to be a severe irritant.	50
Polysorbate 20 (100%)	BCOP assay	Predicted to be a mild irritant.	50

BCOP=Bovine Corneal Opacity and Permeability assay; DMEM= Dulbecco's modified Eagle's medium; HET-CAM=Hen's Egg Test-Chorioallantoic Membrane assay; ICDRG=International Contact Dermatitis Research Group; STE=Short Time Exposure test.

## **REFERENCES**

- 1. Elder, RL. Final report on the safety assessment of polysorbates 20, 21, 40, 60, 61, 65, 80, and 85. *Journal of the American College of Toxicology*. 1984;3(5):1-82.
- Andersen, FA. Final Report on the Safety Assessment of PEG-20 Sorbitan Cocoate; PEG-40 Sorbitan Diisostearate; PEG-2, -5, and -20 Sorbitan Isostearate; PEG-40 and -75 Sorbitan Lanolate; PEG-10, -40, -44, -75, and -80 Sorbitan Laurate; PEG-3, and -6 Sorbitan Oleate; PEG-80 Sorbitan Palmitate; PEG-40 Sorbitan Perisostearate; PEG-40 Sorbitan Peroleate; PEG-3, -6, -40, and -60 Sorbitan Stearate; PEG-20, -30, -40, and -60 Sorbitan Tetraoleate; PEG-60 Sorbitan Tetrastearate; PEG-20 and -160 Sorbitantriisostearate; PEG-18 Sorbitan Trioleate; PEG-40 and -50 Sorbitol Hexaoleate; PEG-30 Sorbitol Tetraoleate Laurate; and PEG-60 Sorbitol Tetrastearate-Addendum to the Final Report on the Safety Assessment of Polysorbates. *International Journal of Toxicology*. 2000;19(Suppl. 2):43-89.
- 3. Wenninger, JA, Canterbery, RC, and McEwen Jr, GN. International Cosmetic Ingredient Handbook and Dictionary. 8 *ed*. Washington, DC: Cosmetics, Toiletries, and Fragrance Association, 2000.
- 4. Nikitakis, J and Breslawec HP. International Cosmetic Ingredient Dictionary and Handbook. 15 ed. Washington, DC: Personal Care Products Council, 2014.
- 5. Food and Drug Administration (FDA). Frequency of use of cosmetic ingredients. FDA Database. 2014. Washington, DC: FDA.
- 6. Andersen, FA. Final report on the safety assessment of PEG-6, -8, and -20 sorbitan beeswax. *International Journal of Toxicology*. 2001;20(Suppl. 4):27-38.
- Bergfeld, WF, Belsito, DV, Hill, RA, Klaassen, CD, Liebler, DC, Marks Jr, JG, Shank, RC, Snyder, PW, and Andersen, FA. Final report of the Cosmetic Ingredient Review Expert Panel: amended safety assessment of triethylene glycol and polyethylene (PEGs) -4, -6, -7, -8, -9, -10, -12, -14, -16, -18, -20, -32, -33, -40, -45, -55, -60, -75, -80, -90, -100, -135, -150, -180, -200, -220, -240, -350, -400, -450, -500, -800, -2M, -5M, -7M, -9M, -14M, -20M, -23M, -25M, -45M, -65M, -90M, -115M, -160M, and -180M and any PEG >= 4. Washington, DC, Cosmetic Ingredient Review. 2010. pp. 1-49.
- 8. Food and Drug Administration (FDA). Frequency of use of cosmetic ingredients. FDA Database. 2015. Washington, DC: FDA.
- Andersen, FA. Annual review of cosmetic ingredient safety assessments 2002/2003. International Journal of Toxicology. 2005;24(Suppl. 1):1-102.
- Andersen, FA. Annual review of cosmetic ingredient safety assessments 2004/2005. International Journal of Toxicology. 2006;26(Suppl. 2):1-89.
- Bergfeld, WF, Belsito, DV, Hill, RA, Klaassen, CD, Liebler, DC, Marks Jr, JG, Shank, RC, Slaga, TJ, Snyder, PW, Andersen, FA, Burnett, CL, and Fiume, M. Final report: Plant-derived fatty acid oils as used in cosmetics. Washington, DC, Cosmetic Ingredient Review. 2011. pp. 1-100.
- Burnett, CL, Bergfeld, WF, Belsito, DV, Klaassen, CD, Marks Jr, JG, Shank, RC, Slaga, TJ, Snyder, PW, and Andersen, FA. Final report on the safety assessment of *Cocos nucifera* (coconut) oil and related ingredients. *International Journal of Toxicology*. 2011;30(Suppl 1):5S-16S.
- 13. Elder, RL. Final report of the safety assessment for acetylated lanolin alcohol and related compounds. *Journal of Environmental Pathology and Toxicology*. 1980;4(4):63-92.
- 14. Elder, RL. Final report on the safety assessment of isostearic acid. Journal of the American College of Toxicology. 1983;2(7):61-74.
- 15. Elder, RL. Final report on the safety assessment of candelilla wax, carnauba wax, Japan wax, and beeswax. *Journal of the American College of Toxicology*. 1984;3(3):1-41.
- 16. Elder, RL. Final report on the safety assessment of butyl stearate, cetyl stearate, isobutyl stearate, isocetyl stearate, isopropyl stearate, myristyl stearate, and octyl stearate. *Journal of the American College of Toxicology*. 1985;4(5):107-146.
- 17. Elder, RL. Final report on the safety assessment of oleic acid, lauric acid, palmitic acid, myrisitic acid, and stearic acid. *Journal of the American College of Toxicology*. 1987;6(3):321-401.
- Andersen, FA. Final report on the safety assessment of triethylene glycol and PEG-4. International Journal of Toxicology. 2006;25(Suppl 2):121-138.
- Bergfeld, WF, Belsito, DV, Hill, RA, Klaassen, CD, Liebler, DC, Marks Jr, JG, Shank, RC, Slaga, TJ, Snyder, PW, Andersen, FA, Fiume, M, and Heldreth, B. Amended safety assessment of alkyl esters as used in cosmetics. Washington, DC, Cosmetic Ingredient Review. 2013. pp. 1-82.
- Andersen, FA. Final report on the safety assessment of sorbitan caprylate, sorbitan cocoate, sorbitan disostearate, sorbitan dioleate, sorbitan distearate, sorbitan isostearate, sorbitan olivate, sorbitan sesquiisosotearate, and sorbitan triisostearate. *International Journal of Toxicology*. 2002;21(Suppl. 1):93-112.

- Bergfeld, WF, Belsito, DV, Hill, RA, Klaassen, CD, Liebler, DC, Marks Jr, JG, Shank, RC, Slaga, TJ, Snyder, PW, Gill, LJ, Fiume, M, and Heldreth, B. Safety assessment of sorbitan esters as used in cosmetics. Washington, DC, Cosmetic Ingredient Review. 2014. pp. 1-26.
- Elder, RL. Final report on the safety assessment of sorbitan stearate, sorbitan laurate, sorbitan sesquioleate, sorbitan oleate, sorbitan tristearate, and sorbitan trioleate. *Journal of the American College of Toxicology*. 1985;4(3):65-121.
- 23. European Chemicals Agency (ECHA). Information on Chemicals-Sorbitan monolaurate, ethoxylated 9005-64-5. http://echa.europa.eu/information-on-chemicals. Date Accessed 1-12-2015.
- 24. European Chemicals Agency (ECHA). Information on Chemicals-Sorbitan monooleate, ethoxylated 9005-65-6. http://echa.europa.eu/information-on-chemicals. Date Accessed 1-12-2015.
- European Chemicals Agency (ECHA). Information on Chemicals-Sorbitan monostearate, ethoxylated 9005-67-8. http://echa.europa.eu/information-on-chemicals. Date Accessed 1-12-2015.
- Abrar, S. and Trathnigg, B. Characterization of commercial polysorbates using different chromatographic techniques. *Tenside, Surfactants, Detergents.* 2009;46(5):280-288.
- Snelling, Jonathon R., Scarff, Charlotte A., and Scrivens, James H. Characterization of Complex Polysorbate Formulations by Means of Shape-Selective Mass Spectrometry. *Analytical Chemistry (Washington, DC, United States)*. 2012;84(15):6521-6529.
- Kociba RJ, McCollister SB, Park C, Torkelson TR, and Gehring PJ. 1,4-Dioxane. I. Results of a 2-year ingestion study in rats. *Toxicol Appl Pharmacol.* 1974;30:275-286.
- Food and Drug Administration (FDA). 1,4-Dioxane. <u>http://www.fda.gov/cosmetics/productandingredientsafety/potentialcontaminants/ucm101566.htm</u>. 10903 New Hampshire Ave, Silver Spring, MD 20993. Date Accessed 9-17-2012.
- 30. Elder RL (ed). Final Report on the Safety Assessment of PEG-2, -6, -8, -12, -20, -32, -40, -50, -100, and -150 Stearates. JACT. 1983;2(7):17-34.
- Personal Care Products Council. 8-16-2014. Concentration of Use by FDA Product Category: Polysorbate and Related Ingredients. Unpublished data submitted by Personal Care Products Council.
- Personal Care Products Council. 12-23-2015. Concentration of Use by FDA Product Category: PEG-30 Sorbitan Beeswax. Unpublished data submitted by Personal Care Products Council. 1 pages.
- European Commission. CosIng database; following Cosmetic Regulation No. 1223/2009. <u>http://ec.europa.eu/consumers/cosmetics/cosing/</u>. Date Accessed 1-14-0015.
- Bremmer HJ, Prud'homme de Lodder LCH, and van Engelen JGM. Cosmetics Fact Sheet: To assess the risks for the consumer; Updated version for ConsExpo. 2006. <u>http://www.rivm.nl/bibliotheek/rapporten/320104001.pdf</u>. Date Accessed 8-24-2011. Report No. RIVM 320104001/2006. pp. 1-77.
- 35. Johnsen MA. The Influence of Particle Size. Spray Technology and Marketing. 2004;14(11):24-27.
- Rothe H, Fautz R, Gerber E, Neumann L, Rettinger K, Schuh W, and Gronewold C. Special aspects of cosmetic spray safety evaluations: Principles on inhalation risk assessment. *Toxicol Lett.* 8-28-2011;205(2):97-104.
- Rothe H. Special aspects of cosmetic spray safety evaluation. 2011. Unpublished information presented to the 26 September CIR Expert Panel. Washington D.C.
- Choi, Han Gon, Rhee, Jong Dal, Yu, Bong Kyu, Kim, Jung Ae, Kwak, Mi Kyung, Woo, Jong Soo, Oh, Dong Hun, Han, Myo Jung, Choi, Jun Young, Piao, Mingguan, and Yong, Chul Soon. The effect of enhancers on the penetration of albuterol through hairless mouse skin. Yakche Hakhoechi. 2006;36(5):321-329.
- Gad, Shayne C., Cassidy, Crystal D., Aubert, Nicolas, Spainhour, Bart, and Robbe, Heide. Nonclinical vehicle use in studies by multiple routes in multiple species. *International Journal of Toxicology*. 2006;25(6):499-521.
- Gopinathan, S, O'Neill, E, Rodriguez, LA, Champ, R, Phillips, M, Mouraldeen, A, Wendt, M, Wilson, AGE, and Kramer, JA. In vivo toxicology of excipients commonly employed in drug discovery in rats. *Journal of Pharmacological and Toxicological Methods*. 2013;68(2):284-295.
- Li, Xiaorong, Wang, Lijuan, Li, Yuhang, Ho, Yeung, Yang, Dongxu, Chen, Yi, Hu, Xiaomin, and Xue, Ming. Polysorbates as novel lipidmodulating candidates for reducing serum total cholesterol and low-density lipoprotein levels in hyperlipidemic C57BL/6J mice and rats. *European Journal of Pharmacology*. 2011;660(2-3):468-475.
- 42. Eskandani, Morteza, Hamishehkar, Hamed, and Ezzati Nazhad Dolatabadi, Jafar. Cyto/Genotoxicity Study of Polyoxyethylene (20) Sorbitan Monolaurate (Tween 20). DNA and Cell Biology. 2013;32(9):498-503.

- Galloway, SM, Bloom, AD, Resnick, M, Margolin, BH, Nakamura, F, Archer, P, and Zeiger, E. Development of a standard protocol for in vitro cytogenetic testing with Chines hamster ovary cells: Comparison of results for 22 compounds in two laboratories. *Environmental Mutagenisis*. 1985;7(1):1-51.
- Basketter, D. A., York, M., McFadden, JP, and Robinson, M. K. Determination of skin potential in the human 4-h patch test. *Contact Dermatitis*. 2004;51(1):1-4.
- Lee, J. K., Kim, D. B., Kim, J. I., and Kim, P. Y. In vitro cytotoxicity tests on cultured human skin fibroblasts to predict skin irritation potential of surfactants. *Toxicology In Vitro*. 2000;14(4):345-349.
- Robinson, M. K, McFadden, JP, and Basketter, D. A. Validity and ethics of the human 4-h patch test as an alternative method to assess acute skin irritation potential. *Contact Dermatitis*. 2001;45(1):1-12.
- Lewis, R. W., McCall, J. C., and Botham, P. A. A comparison of two cytotoxicity tests for predicting the ocular irritancy of surfactants. *Toxicology In Vitro*. 1993;7(2):155-158.
- 48. Ohno, Y., Kaneko, T., Inoue, T, Morikawa, Y, Yoshida, T, Fujii, A, Masuda, M, Ohno, T, Hayashi, M, Momma, J, Uchiyama, T, Chiba, K, Ikeda, N, Imanishi, Y, Itakagaki, H, Kakishima, H, Kasai, Y, Kurishita, A, Kojima, H, Matsukawa, K, Nakamura, T, Ohkoshi, K, Okumura, H, Saijo, K, Sakamoto, K, Suzuki, T, Takano, K, Tatsumi, H, Tani, N, Usami, M, and Watanabe, R. Interlaboratory validation of the in vitro eye irritation test for cosmetic ingredients. (1) Overview of the validation study and Draize scores for the evaluation of the test. *Toxicology In Vitro*. 1999;13(1):73-98.
- Okamoto, Y., Ohkoshi, K., Itagaki, H., Tsuda, T., Kakishima, H., Ogawa, T., Kasai, Y., Ohuchi, J., Kojima, H., Kurishita, A., Kaneko, T., Matsushima, Y., Iwabuchi, Y., and Ohno, Y. Interlaboratory validation of the in vitro eye irritation tests for cosmetic ingredients. 3. Evaluation of the hemolysis test. *Toxicology In Vitro*. 1999;13(1):115-124.
- Hayashi, Kazuhiko, Mori, Taeko, Abo, Takayuki, Ooshima, Kenichi, Hayashi, Takumi, Komano, Tomoko, Takahashi, Yutaka, Sakaguchi, Hitoshi, Takatsu, Akihiko, and Nishiyama, Naohiro. Two-stage bottom-up tiered approach combining several alternatives for identification of eye irritation potential of chemicals including insoluble or volatile substances. *Toxicology In Vitro*. 2012;26(7):1199-1208.
- Pfannenbecker, U., Bessou-Touya, S., Faller, C., Harbell, J., Jacob, T., Raabe, H., Tailhardat, M., Alepee, N., De Smedt, A., De Wever, B., Jones, P., Kaluzhny, Y., Le Varlet, B., McNamee, P., Marrec-Fairley, M., and Van Goethem, F. Cosmetics Europe multi-laboratory prevalidation of the EpiOcular reconstituted human tissue test method for the prediction of eye irritation. *Toxicology In Vitro*. 2013;27(2):619-626.
- Burnett, CL, Fiume, M, Bergfeld, WF, Belsito, DV, Klaassen, CD, Marks Jr, JG, Shank, RC, Slaga, TJ, Snyder, PW, and Andersen, FA. Final report: derived fatty acid oils as used in cosmetics. Washington, DC, Cosmetic Ingredient Review. 2011. pp. 1-100.
- Elder, RL. Final report on the safety assessment of coconut oil, coconut acid, hydrogenated coconut acid, and hydrogenated coconut oil. Journal of the American College of Toxicology. 1986;5(3):103-121.
- Nikitakis, JM and McEwen Jr, GN. CTFA Compendium of Cosmetic Ingredient Composition Specifications. Washingtonm, DC: Cosmetic, Toiletry, and Fragrance Association, 1990.
- National Institutes of Health, National Institute of Environmental Health Service. Chemical Effects in Biological Systems Polysorbate 20 -M910077; CASRN: 9005-64-5. <u>http://ntp.nichs.nih.gov/testing/status/agents/ts-m910077.html</u>. Date Accessed 1-21-2015.
- McCutcheon's Detergents and Emulsifiers. North American Edition *ed.* Ridgewood, NJ: Allured Published Corporation; McCutcheon's Division, 1973.
- 57. Estrin, NF. CTFA Standards: Cosmetic Ingredient Descriptions. Washington, DC: Cosmetic, Toiletry, and Fragrance Association, 1974.
- 58. Japan Cosmetic Industry Association (JCIA). Tokyo, Yakuji Nippo, Ltd. 1979.
- 59. The United States Pharmacopeia. 19 ed. Rockville, MD: United States Pharmacopeial Convention, 1975.
- 60. Mittal, KL. Determination of CMC (critical micelle concentration) of polysorbate 20 in aqueous solution by surface tension method. *Journal of Pharmaceutical Sciences*. 1972;61(8):1334-1335.
- 61. Nikitakis, JM and McEwen Jr, GN. CTFA compendium of Cosmetic Ingredient Composition. Washington, DC: Cosmetic, Toiletry, and Frangrance Association, 1990.
- 62. Food Chemicals Codex. Washington, DC: National Academy of Sciences, 1972.
- 63. Greenberg, LA and Lester, D. Handbook of Cosmetic Materials. New York: Interscience Publishers, 1954.
- 64. Grant, J. Hackh's Chemical Dictionary. 4 ed. New York: McGraw-Hill Book Company, 2015.
- 65. Windholz, M. The Merck Index. 9 ed. Rahway, NJ: Merck and Company, 1976.

- 66. National Institutes of Health, National Institute of Environmental Health Service. Chemical Effects in Biological Systems Polysorbate 80 -M910077; CASRN: 9005-65-6. <u>http://ntp.niehs.nih.gov/testing/status/agents/ts-10122-n.html</u>. Date Accessed 1-20-2015.
- 67. Nikitakis, JM and McEwen Jr, GN. CTFA Compedium of Cosmetic Ingredients Composition Descriptions II. Washington, DC: Cosmetic, Toiletry, and Fragrance Association, 1990.